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ABSTRACT 
 
 The Gangliosidoses, to include GM1 gangliosidosis and Sandhoff disease 
are a class of incurable lysosomal storage disorders characterized by an 
abnormal accumulation of gangliosides leading to progressive 
neurodegeneration and eventually death.  GM1 gangliosidosis is caused by a 
genetic defect in the lysosomal-specific acid β-galactosidase, which results in the 
massive accumulation of ganglioside GM1 primarily in the central nervous 
system (CNS).  Sandhoff disease (SD) results from a defect in the β-subunit of β-
Hexosaminidase A and leads to the accumulation of ganglioside GM2 and its 
asialo derivative (GA2).  As there are no effective therapies for these 
glycosphingolipid (GSL) storage disorders, I studied substrate reduction therapy 
(SRT), stem cell therapy, and adeno-associated viral (AAV) gene therapy in 
neonatal mice as early intervention therapies and were effective in reducing CNS 
GSL storage.  In addition, AAV gene therapy was also evaluated in the adult 
GM1 gangliosidosis mice.  Furthermore, analysis of the brain lipids in mice, cats, 
and humans with Sandhoff disease revealed that the SD cat model is 
intermediate between the SD mouse and the SD patient with respect to GM2 and 
GA2 accumulation.  These findings are the first to compare the different 
therapies and provide valuable information for the translation of mouse studies to 
clinical trials in patients. 
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CHAPTER ONE 
INTRODUCTION 
 
Gangliosides 
Gangliosides are acidic sialic acid-containing glycosphingolipids (GSLs) 
which are present in the plasma membrane in virtually all vertebrate cells 
(Ledeen and Yu 1982; Hakomori 1986).  Gangliosides are expressed in 
mammalian tissues, and are enriched in tissues of the central nervous system 
(CNS), in particular the gray matter (Ledeen 1983, 1985).  Neurons contain the 
bulk of cortical ganglioside because of their greater number and surface area 
(Ledeen 1983).  GSLs are amphiphilic, and consist of an oligosaccharide head 
group, which is attached to a lipophilic ceramide, comprising of a sphingosine 
base and a long-chain fatty acid (Ledeen 1985).  The oligosaccharide chain 
consists of different combinations of glucose, galactose, N-acetylgalactosamine, 
and N-acetylglucosamine, which can vary from a single sugar to many as 4 
sugars (Yogeeswaran et al. 1972; Ledeen 1983; Yu 1993).  The ceramide portion 
of the GSL is anchored into the outer leaflet of the lipid bilayer and its 
oligosaccharide head group is projected into the extracellular environment 
(Figure 1).    
Gangliosides can be distinguished from other GSLs in that they contain 
one or more negatively charged sialic acid (SA) residues.  These 9-carbon SA 
structures are expressed in two forms, N-acetylneuraminic acid (NeuAc or 
 2 
NANA) or N-glycolylneuraminic acid (NeuGc or NGNA) and are attached to the 
galactose subunits of the oligosaccharide chain (Yu and Ledeen 1970; Ledeen 
and Yu 1982; Ledeen 1983; Kawano et al. 1995).  The SA NeuGC or NGNA is 
only present in non-neural tissue.  The combination of the two different SA 
species, the number of SA species, the length of the oligosaccharide chain, and 
the variation in the fatty acid chain length of the ceramide moiety contribute to the 
structural diversity of gangliosides (Ledeen and Yu 1982; Sonnino et al. 1982; 
Ando and Yu 1984).  
 Gangliosides have been shown to influence several important biological 
processes such as cell adhesion, cell growth, angiogenesis, and signal 
transduction (Schengrund 1990; Karlsson et al. 1993; Hakomori 1996; Alessandri 
et al. 1997; Manfredi et al. 1999; Abate et al. 2006).  Studies have also shown 
that gangliosides may interact with toxins, viruses, bacteria, as well as 
modulating membrane receptors (Ledeen 1983; Sandhoff and van Echten 1994; 
Hakomori 1993).  Despite all of this work, the role of gangliosides is still not 
entirely clear. 
 
Ganglioside Synthesis and Degradation 
 Ganglioside synthesis occurs in the Golgi through the control of a complex 
of multi-glycosyltransferases and sialyltransferases (Roseman 1970; Caputto et 
al. 1974; van-Echten and Sandhoff 1989; Giraudo and Maccioni 2003).  This 
process involves the synthesis of each ganglioside species on it own microsomal 
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assembly where each metabolic intermediate becomes the substrate for the next 
biosynthetic reaction (Roseman 1970; Caputto et al. 1974; Giraudo and Maccioni 
2003). Following synthesis, gangliosides are packaged into vesicles, which bud 
off from the Golgi compartments, and travel to the cell surface, where they fuse 
with the plasma membrane (Young et al. 1992; Sandhoff and van Echten 1994).  
 Ganglioside biosynthesis can be classified into four metabolic pathways, 
the “asialo”, “a”, “b”, and “c” pathways (Figure 2). The asialogangliosides lack 
sialic acid residues, whereas, gangliosides synthesized through the “a”, “b”, and 
“c” pathways have one, two, and three sialic acids, respectively (Pohlentz et al. 
1988; Iber and Sandhoff 1989; Iber et al. 1991; Sandhoff and van Echten 1994).  
In mammalian brain, the gangliosides in the “a” and “b” pathway constitute the 
predominant species of gangliosides (Svennerholm 1963; Suzuki 1965; 
Svennerholm and Vanier 1972; Yu and Ando 1980).    
Ganglioside degradation also occurs in a stepwise fashion but in reverse 
order of biosynthesis. Gangliosides are endocytosed from the plasma membrane 
and transported to the lysosome through various endosomal compartments 
(Ledeen 1983; Schwarzmann and Sandhoff 1990; Sandhoff and Kolter 1997).  In 
the lysosomes, gangliosides are completely or partially degraded by the 
sequential removal of individual sugar residues by substrate-specific acidic 
hydrolytic enzymes and activator proteins (Sandhoff and van Echten 1994; 
Sandhoff and Kolter 1997).  The by-products of degradation, sugars (glucose, 
galactose, hexosamine), lipids (ceramide, sphingosine, and fatty acid), and sialic 
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acid residues are recycled to the Golgi for lipid biosynthesis and re-glycosylation 
(Schwarzmann and Sandhoff 1990). 
  
Ganglioside Storage Diseases 
Dysfunctional lysosomal hydrolytic enzymes and activator proteins can 
cause defects in the catabolic GSL pathway resulting in a wide variety of 
lysosomal storage disorders (LSDs) as well as the ganglioside storage diseases 
(Kolter and Sandhoff 1998).  The gangliosidoses comprise of GM1 gangliosidosis 
and the GM2 gangliosidoses to include Tay-Sachs disease and Sandhoff 
disease, and are characterized by abnormal ganglioside accumulation in the 
CNS (Gravel et al. 1995; Suzuki et al. 1995).  Most inherited diseases of GSL 
metabolism affect the hydrolytic pathways but not the synthetic pathways, 
suggesting conservation in GSL synthesis and patterning on the cell surface 
(Sandhoff and Kolter 1997).  However, it was recently shown in an Old Order 
Amish pedigree, that loss of GM3 synthase resulted in infantile-onset 
symptomatic epilepsy (Simpson et al. 2004).  This is the first report showing that 
disruption of a GSL synthetic enzyme results in a human disease.   
Generalized gangliosidosis or GM1 gangliosidosis was first described in 
1959 by Norman et al. (Norman et al. 1959). It was not until 1968 that the 
biochemical deficiency in GM1 gangliosidosis was explained (Okada and O'Brien 
1968). GM1 gangliosidosis is an autosomal recessive GSL storage disease 
caused by a genetic deficiency of the lysosomal acid β-galactosidase (β-gal), 
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which results in the accumulation of ganglioside GM1 and its asialo-form (GA1) 
primarily in the CNS (Figure 3).  The onset of disease ranges from infancy to 
adulthood, which correlates with relative β-gal activity.  In the infantile form, 
presentation of the disease is associated with rapid motor deterioration, macular 
cherry red spot, and skeletal dysplasia (Suzuki et al. 1995).  Pathogenesis in 
GM1 gangliosidosis is marked with neuronal damage or death, inflammation, and 
progressive neurological deterioration (Suzuki et al. 1995). In addition, myelin 
abnormalities such as white matter changes revealed by MRI analysis and 
myelin-enriched lipid reductions occur in the human patients and are also seen in 
the canine disease model (Kaye et al. 1992; Kroll et al.; Folkerth et al. 2000; Van 
Der Voorn et al. 2004; Denny et al. 2006).  Although the biochemical deficiency 
in GM1 gangliosidosis was first described in the late 1960’s, there is still no 
treatment available for patients (Okada and O'Brien 1968; Suzuki et al. 1995). 
 The GM2 gangliosidoses are characterized by an abnormal accumulation 
of ganglioside GM2, leading to progressive neurodegeneration (Neufeld 1991; 
Gravel et al. 1995). GM2 catabolism occurs through the concerted actions of β-
hexosaminidase A, which consists of an α and a β subunit encoded by the Hexa 
and Hexb genes, respectively, and the GM2 activator protein (Figure 4).  The 
GM2 gangliosidoses result from inherited defects in either the Hexa or the Hexb 
gene or in GM2 activator protein, and lead to Tay-Sachs disease (B variant), 
Sandhoff disease (O variant), or GM2 activator protein deficiency (AB variant), 
respectively.   
 6 
 In 1881, Warren Tay, a British ophthalmologist, first observed the classical 
clinical characteristic of the cherry-red spot in the retina of a patient with “infantile 
amaurotic idiocy” (Tay 1881; Gravel et al. 1995).  In 1896, the American 
neurologist, Bernard Sachs noticed the prevalence of the disease in Ashkenazi 
Jewish families and created the term “amaurotic family idiocy” (Sachs 1896; 
Gravel et al. 1995).  However, it was not until the 1930’s that the German 
biochemist, Ernst Klenk identified the storage material in the brains of patients 
with amaurotic idiocy and named this material “gangliosides” because of its 
prevalence in normal ganglion cells (Gravel et al. 1995).   In 1969, several 
investigators, including Konrad Sandhoff discovered that the enzyme, β-
hexosaminidase A was absent in Tay-Sachs disease patients (Okada and 
O'Brien 1969; Sandhoff 1969).  
 Sandhoff disease (SD) arises from an autosomal recessive mutation in the 
Hexb gene and as a result, patients lack activity of both β-hexosaminidase 
isozymes A (αβ) and B (ββ).  Consequently, they accumulate GM2 and also 
oligosaccharides and other hexosaminidase substrates within lysosomes 
(Neufeld 1991; Gravel et al. 1995). There are three clinical forms of SD, which 
include infantile-, juvenile-, and adult-onset forms.  The β-hexosaminidase A 
enzyme activity in SD patients correlate with disease onset, ranging from little or 
no activity in the juvenile- and the infantile-onset forms to measurable activity in 
the adult-onset form (Gravel et al. 1995).  Patients with infantile-onset generally 
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succumb to the disease within the first few years of life while life expectancy in 
adult-onset patients can vary widely (Gravel et al. 1995). 
 
 
Mouse Models of the Gangliosidoses 
 Mouse models of the gangliosidoses are useful tools in that they 
reproduce the biochemical deficiency, the neurochemical accumulation, and the 
pathological consequence observed in the human diseases.  Although cognitive 
defects in the mouse models of the gangliosidoses have yet to be determined, it 
was recently shown that the mice are also blind, recapitulating another patient 
phenotype (Denny et al. 2007). Mice lacking β-gal activity was generated using 
homologous recombination and embryonic stem cell technology (Hahn et al. 
1997; Matsuda et al. 1997).  The β-gal -/- mice express residual β-gal activity and 
elevation of GM1 and GA1, mimicking the infantile form of GM1 gangliosidosis.  
Despite CNS GM1 accumulation from as early as postnatal day 5 (p-5), the β-gal 
-/- mice do not show behavioral abnormalities until adult ages (Matsuda et al. 
1997; Kasperzyk et al. 2004; Ichinomiya et al. 2007). In contrast to infantile onset 
patients where ganglioside accumulation leads to behavioral and developmental 
abnormalities within the first few years of life, β-gal-deficient mice are 
phenotypically indistinguishable from normal mice until adult ages (Hahn et al. 
1997).  Also, GA1 accumulation is greater in the murine models than in patients 
with GM1 gangliosidosis most likely because of a more active sialidase specific 
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to this substrate (Hahn et al. 1997). The β-gal -/- mice display ataxia, hind limb 
paralysis, and difficulty in walking and can be used to study GM1 gangliosidosis 
(Hahn et al. 1997; Ichinomiya et al. 2007).  
 Mouse models of the GM2 gangliosidoses were generated by targeted 
disruption of Hexa, Hexb, and the GM2 activator protein (GM2AP) to produce 
mice that mimic Tay-Sachs disease (TSD), SD, and GM2 activator deficiency, 
respectively (Yamanaka et al. 1994; Sango et al. 1995; Phaneuf et al. 1996; Liu 
et al. 1997).  Although the TSD mice lack β-Hexosaminidase A activity and 
accumulate modest amounts of GM2, these mice do not display abnormal 
phenotypic behavior (Yamanaka et al. 1994; Sango et al. 1995; Phaneuf et al. 
1996). It has been shown that an alternative GM2 degradative pathway in mice 
spares the TSD mice from overt phenotypic behavior associated with disease 
(Sango et al. 1995; Yuziuk et al. 1998; Bertoni et al. 1999).   
 In the “classic pathway,” GM2 is catabolyzed to GM3 by β-
Hexosaminidase A (αβ) and the GM2AP in both mice and humans (Gravel et al. 
1995; Yuziuk et al. 1998) (Figure 5). In the “alternative pathway” in mice, GM2 
degradation can also occur via a sialidase (Sango et al. 1995).  GA2 is further 
degraded to lactosylceramide (LacCer) by β-Hexosaminidase A (αβ) + GM2AP 
or, to a minor extent by β-Hexosamindase B (ββ) + GM2AP (Yuziuk et al. 1998).  
In the TSD mice, the “classic pathway” is blocked by defects in the α-subunit in 
β-Hexosaminidase A.  However, GM2 degradation can continue in the 
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“alternative pathway” because β-Hexosaminidase B (ββ) is still functional.  As a 
result, the TSD mice do not show phenotypic behavior associated with disease.     
In the SD mouse model, Hexb -/- mice lack activity of both β-
hexosaminidase isozymes A (αβ) and B (ββ) and express only about 2% total 
hexosaminidase activity (from β-hexosaminidase S - αα) of wild-type level.  As a 
result, SD mice accumulate both GM2 and its asialo derivative, GA2 in the CNS.  
At around 100 days of age, the SD mice begin to display neurological problems 
such as lethargy, ataxia, and failure to thrive (Sango et al. 1995; Denny et al. 
2006).  The SD mice mimic the pathological, biochemical, and clinical 
abnormalities of the human disease and can be used to explore new therapeutic 
approaches.  
 
 My dissertation research tested different therapeutic approaches for the 
early intervention treatment of the ganglioside storage diseases, GM1 
gangliosidosis and Sandhoff disease.  The goal was to analyze the 
neurochemical outcome including brain lipids mouse models of the 
gangliosidoses following substrate reduction therapy, stem cell therapy, and 
gene therapy initiated during neonatal ages.  Gene therapy had the greatest 
efficacy in normalizing the neurochemical phenotype and was also examined in 
adult mice.  
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Figure 1.  Ganglioside structure and orientation in the plasma membrane.  The 
lipophilic ceramide portion inserts into the plasma membrane while the 
oligosaccharide head group extends into the extracellular environment.  
 
The roman numerals represent individual sugar residues that make up the GSL 
oligosaccharide chain.   
I = glucose 
II = galactose 
III = N-acetylgalactosamine 
IV = galactose 
 
The letters A, B, and C represent sialic acid residues (NeuAc or NANA).  
Ceramide (Cer) is embedded in the plasma membrane.  
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Figure 2.  Glycosphingolipid Biosynthetic Pathways.  GSL biosynthesis begins 
with ceramide (Cer).  Ganglioside biosynthesis proceeds by the action of multiple 
glycosyltransferases and sialyltransferases, where the product of one enzymatic 
reaction is the substrate for the next biosynthetic reaction.  Ganglioside synthesis 
is divided into three major metabolic pathways, the “a”, “b”, and “c” pathways.  In 
addition, the “asialo” pathway consists of neutral GSLs and gangliosides.  
Abbreviations: Glc, glucose; Gal, galactose; GalNAc, N-acetylgalactosamine; SA, 
sialic acid.  Adapted from Proia (Proia 2003).   
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Figure 3. GM1 ganglioside. Modified from Expert Reviews in Molecular Medicine, 
2002. 
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Figure 4. GM2 ganglioside. Modified from Expert Reviews in Molecular Medicine, 
2002. 
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Figure 5.  Ganglioside Catabolic Pathway.  Ganglioside catabolism occurs 
through the “classic pathway” in both humans and in mice.  An “alternative 
pathway” exists in mice in which GM2 degradation can occur in the absence of β-
Hexosaminidase A.  Adapted from Sango et al. (Sango et al. 1995). 
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CHAPTER TWO 
N-butyldeoxygalactonojirimycin Reduces Brain Ganglioside and GM2 Content in 
Neonatal Sandhoff Disease Mice 
 
INTRODUCTION 
 
Substrate Reduction Therapy 
 Most current therapies for the ganglioside storage diseases focus on 
increasing residual lysosomal enzyme to compensate for the underlying enzyme 
deficiency.  This includes enzyme replacement therapy, bone marrow 
transplantation, gene therapy and stem cell therapy (Chavany and Jendoubi 
1998; Jeyakumar et al. 2002; Schiffmann and Brady 2002; Takaura et al. 2003; 
Shihabuddin et al. 2004; Lee et al. 2007).  Although pharmacological chaperones 
have been shown to enhance the activity of β-Hexosaminidase A, this work has 
been done primarily in vitro and it is not yet known if this could be effective in vivo 
(Tropak et al. 2004; Maegawa et al. 2007; Tropak et al. 2007).  In contrast to 
these therapies, substrate reduction therapy (SRT) aims to decrease the rate of 
GSL biosynthesis to counterbalance the impaired rate of catabolism (Radin 1982; 
Liu et al. 1999; Tifft and Proia 2000; Platt et al. 2001; Butters et al. 2003; Platt et 
al. 2003; Kasperzyk et al. 2004).  
 Figure 6 describes the rationale for SRT in GSL storage disorders is 
described.  GSL metabolism in the cartoon is depicted by a faucet (GSL 
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biosynthesis), a sink (pool of GSLs), and a drain (GSL catabolism).  Panel a 
illustrates GSL metabolism in a normal person, where GSLs (water) are 
degraded efficiently by adequate enzyme (sink drain).  Panel b shows GSL 
metabolism in a ganglioside storage patient.  The amount of enzyme is 
insufficient to degrade the influx of GSLs and as a result, GSLs accumulates.  
SRT in affected individuals is shown in Panel c.  SRT aims to decrease GSL 
biosynthesis to compensate for impaired catabolism, therefore preventing 
abnormal accumulation.   
 
Imino Sugar – NB-DGJ 
 N-butyldeoxygalactonojirimycin (NB-DGJ) is an imino sugar that inhibits 
glucosylceramide synthase (GlcCerS), which catalyzes the first committed step in 
GSL biosynthesis (Butters et al. 2003); Figure 7).  GSLs are synthesized in a 
stepwise manner in the endoplasmic reticulum and Golgi apparatus and are 
sequentially degraded in the lysosomes (Sandhoff and Conzelmann 1984; 
Sandhoff et al. 1989; Platt and Butters 2004; Platt and Walkley 2004).  
Glucosylceramide (GlcCer) is the precursor for GSL biosynthesis, including 
gangliosides of the ‘a’ and ‘b’ metabolic pathways.  The rationale for SRT using 
NB-DGJ is to inhibit the formation of GlcCer, thereby inhibiting GSL biosynthesis, 
and preventing abnormal accumulation (Kasperzyk et al. 2004).   
SRT using N-butyldeoxynojirimycin (NB-DNJ, miglustat, Zavesca®), the 
glucose analog of NB-DGJ (Figure 8), is effective in reducing pathogenesis in 
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adult mouse models of Tay-Sachs disease and Sandhoff disease (Platt et al. 
1997; Jeyakumar et al. 1999; Jeyakumar et al. 2002). Zavesca® has also been 
approved for the treatment of type 1 Gaucher disease, a GSL lysosomal storage 
disease characterized by non-neuronal accumulation of glucosylceramide and 
under clinical trial for late onset Tay-Sachs disease, type 3 Gaucher disease, and 
Niemann-Pick type C disease (Cox et al. 2000; Cox et al. 2003; Lachmann 2003; 
Moyses 2003; Elstein et al. 2004; Pastores et al. 2005; Patterson et al. 2007). 
However, adverse effects such as weight loss and lymphoid organ shrinkages 
were observed in mice treated with Zavesca® (Platt et al. 1997; Andersson et al. 
2000).   On the other hand, NB-DGJ permits greater dose escalation and is not 
associated with any adverse effects (Andersson et al. 2004; Kasperzyk et al. 
2004). 
 Previous studies showed that NB-DGJ inhibited ganglioside and neutral 
GSL biosynthesis by approximately 90% in cultured whole mouse embryos 
without affecting viability, growth, or morphology (Brigande et al. 1998).  Oral 
administration of NB-DGJ for six weeks in adult SD mice increased life 
expectancy and decreased GSL storage without obvious adverse effects 
(Andersson et al. 2004).  Synergistic effects were observed when combining SRT 
with other therapies such as bone marrow transplantation or administration of 
non-steroidal anti-inflammatory drugs, suggesting combinatory treatments may 
provide greatest efficacy (Jeyakumar et al. 2001; Jeyakumar et al. 2004).  
Recent studies show that NB-DGJ is effective in reducing total brain ganglioside 
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and GM1 content in neonatal mice with GM1 gangliosidosis (Kasperzyk et al. 
2004).  In a follow-up study, GM1 gangliosidosis mice were treated with NB-DGJ 
during critical stages of neurodevelopment.  This treatment reduced total brain 
and cerebellar ganglioside and GM1 content without affecting myelination; 
(Kasperzyk et al. 2005; Kasperzyk et al. 2004).  These results indicate that SRT 
with NB-DGJ is effective in reducing neurochemical pathology and that treatment 
at early neonatal ages may be an effective method for disease management.  
 
In this study, we evaluated SRT using NB-DGJ at neonatal ages in a 
mouse model for SD.  Our results show that GM2 accumulates early in SD mice 
and that NB-DGJ significantly reduces total brain ganglioside and GM2 content 
without producing adverse effects.  Furthermore, NB-DGJ did not alter CNS 
phospholipid composition.  We suggest that the initiation of SRT with NB-DGJ at 
neonatal ages may be an effective early intervention therapy for GM2 
gangliosidoses.   
 
MATERIALS AND METHODS 
 
Mice 
 The SV/129 Hexb -/- mice were obtained from Dr. Richard Proia (NIH).  
These mice were derived by disruption of the murine Hexb gene and transferring 
this gene into the mouse genome through homologous recombination and 
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embryonic stem cell technology as previously described (Sango et al. 1995).  
Hexb -/- mice were derived from crosses of Hexb +/- females with Hexb -/- 
males.  Genotypes of mice were determined by measuring the specific activity of 
total hexosaminidase using a modification of the Galjaard procedure as 
previously described (Galjaard 1980; Hauser et al. 2004).   We previously 
showed that Hexb +/+ and Hexb +/- mice showed similar behavior, brain lipid 
content, and tissue histology (Denny et al. 2006).  Therefore, for our studies, we 
used Hexb +/- mice as our controls.  Hexb +/- and Hexb -/- mice were 
propagated in the Boston College Animal Facility and were housed in plastic 
cages with filter tops containing Sani-Chip bedding (P.J. Murphy Forest Products 
Corp., Montville, NJ, USA).  Other conditions were as we recently described 
(Kasperzyk et al. 2004).  All animal experiments were carried out with ethical 
committee approval in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care Committee. 
 
NB-DGJ Treatment 
 NB-DGJ was purchased from Toronto Research Chemicals, Inc. (North York, 
Ontario, Canada).  Neonatal Hexb -/- mice were injected with a Hamilton syringe 
(26 gauge, point style 2, 0.5 inch needle length) daily (ip) from postnatal day 2 (p-
2) to p-5 with either vehicle (0.9% saline) or NB-DGJ at 600 mg/kg body weight.  
Saline was also injected in the control Hexb +/- mice.  We are considering NB-
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DGJ as an effective early intervention therapy for infantile Sandhoff disease, 
therefore, treatment of normal mice would not be relevant.  The volume of saline 
or NB-DGJ injected per pup ranged between 6-15 µL depending on individual 
pup body weight.  This study was based on previous work which showed that 
600 mg/kg/day of NB-DGJ injected from p-2 to p-5 in GM1 gangliosidosis mice 
was effective in reducing brain gangliosides without producing adverse effects 
(Kasperzyk et al. 2004).  Body weights were measured and brains were collected 
on dry ice approximately 4 hours after the final injection on p-5 and were stored 
at -80°C.   
 
Isolation and Purification of Lipids 
Total Lipid Extraction 
 Total lipids were extracted using modifications of previously described 
procedures (Seyfried et al. 1978; Hauser et al. 2004; Kasperzyk et al. 2004; 
Kasperzyk et al. 2005).  Briefly, frozen brain samples were lyophilized for 24 
hours using a LabCon Co 4.5L Freeze Dryer (LabCon Co, Kansas City, MO).  
Dry weights were measured on a Mettler Toledo, AB54-S balance (Mettler 
Toledo, Greifensee, Switzerland). Total lipids were extracted from the lyophilized 
brain samples in a solution of 5 mL of chloroform (CHCl3):methanol (CH3OH) (1:1 
by volume) and 0.5 mL distilled water (dH2O).  The samples were placed on a 
magnetic stirrer at room temperature for at least 8 hours and then centrifuged for 
15 minutes at 1200 g. The supernatant was collected and the pellet was washed 
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with 2 mL CHCl3:CH3OH (1:1 by volume) and centrifuged as before.  The 
combined supernatants were converted to a CHCl3:CH3OH:dH2O ratio of 30:60:8 
(solvent A) by adding 2.5 mL of CHCl3, 8.5 mL of CH3OH, and 1.6 mL of dH2O, 
respectively.   
 
Column Chromatography 
 Neutral and acidic lipids were separated using DEAE-Sephadex (A-25, 
Pharmacia Biotech, Upsala, Sweden) column chromatography as previously 
described (Macala et al. 1983).  DEAE-Sephadex was prepared in bulk by 
washing the resin three times with solvent B (CHCl3:CH3OH:0.8 M Na acetate, 
30:60:8 by volume), equilibrating in solvent B overnight, followed by washing 
three times with solvent A (CHCl3:CH3OH:dH20, 30:60:8 by volume) until neutral.  
The total lipid extract, suspended in solvent A, was then applied to a DEAE-
Sephadex column (1.2 mL bed volume) that had been equilibrated prior with 
solvent A.  The column was washed twice with 20 mL solvent A and the entire 
neutral lipid fraction, consisting of the initial eluent plus washes, was collected.  
This fraction contained cholesterol, phosphatidylcholine, 
phosphatidylethanolamine and plasmologens, sphingomyelin, and neutral GSLs 
to include cerebrosides and asialo-GM2 (GA2).  Next, acidic lipids were eluted 
from the column with 35 mL solvent B.  
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Ganglioside Purification 
 The acidic lipid fraction containing gangliosides was dried by rotary 
evaporation and transferred to a 15 mL graduated conical glass tube using 
CHCl3:CH3OH (1:1 by volume) and adjusted to 7 mL using the same solvent.  
Water was added and the mixture was inverted, vortexed, and centrifuged for 
about 15 minutes at 1200 g to partition gangliosides into the upper phase (Folch 
et al. 1957; Seyfried et al. 1978).   The upper aqueous phase was removed and 
the lower organic phase was washed once with 4.5 mL of the Folch ‘pure solvent 
upper phase’ (CHCl3:CH3OH:dH20, 3:48:47 by volume).  The combined upper 
phases, containing gangliosides, were adjusted to 11 mL using CH3OH.  
 
Resorcinol Assay 
 An aliquot of the ganglioside fraction (Folch upper phase) was evaporated 
in a vacuum oven (Precision model 29) and analyzed for sialic acid content using 
a modified resorcinol assay (Svennerholm 1957; Miettinen and Takki-Luukkainen 
1959; Suzuki 1964).  N-acetylneuraminic acid (Sigma # A 9646, St. Louis, MO, 
USA) (1, 3, and 6 µg) was used as an external standard.  Samples were 
dissolved in 1 mL of resorcinol reagent (40 mL concentrated HCl, 0.125 mL 0.1 
M copper sulfate, 5 mL 2% resorcinol stock, brought to 50 mL with distilled 
water):dH2O (1:1 by volume), boiled for 17 minutes, and then cooled in an ice 
bath.  Butyl acetate:1-butanol (1.5 mL, 85:15 by volume) was then added to each 
sample, and the samples were vortexed and centrifuged at 1200 g.  The 
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supernatant was then carefully removed and analyzed in crystal cuvettes at 580 
nm in the Shimadzu UV-1601 UV-visible spectrophotometer (Shimadzu, Kyoto, 
Japan).  
 
Base Treatment and Desalting 
 After removing aliquots for the resorcinol assay, the ganglioside fraction was 
evaporated under a stream of nitrogen and treated with mild base (1 mL of 0.5 M 
NaOH) in a shaking water bath at 37°C for 1.5 hours.  Base and salts were 
separated from the gangliosides using a modification of a previously described 
method (Williams and McCluer 1980).  Briefly, the sample was applied to a C18 
reverse-phase Bond Elute column (Varian, Harbor City, CA, USA) that was 
equilibrated with 5 mL each of CHCl3:CH3OH (1:1  by volume), CH3OH, and then 
0.1 M NaCl.  The column was washed with 30 mL of dH2O to remove salts.  
Gangliosides were eluted from the column with 2 mL of CH3OH and then 
followed by 4 mL of CHCl3:CH3OH (1:1  by volume).  Samples were evaporated 
under nitrogen, re-susupended in 5 mL of CHCl3 : CH3OH (1:1  by volume), and 
then stored at 4°C.   
 
Acidic Phospholipid Purification 
 After the ganglioside fraction (Folch upper phase) was transferred, the acidic 
phospholipid fraction (Folch lower phase) was evaporated under a stream of 
nitrogen and resuspended in 10 mL of CHCl3:CH3OH (1:1 by volume).  This 
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fraction contained fatty acids, cardiolipin, phosphatidylserine, 
phosphatidylinositol, and sulfatides. 
 
Neutral Lipid Purification 
 Neutral lipids were dried by rotary evaporation and resuspended in 10 mL 
CHCl3:CH3OH (2:1 by volume).  To further purify GA2, a 4 mL aliquot of the 
neutral lipid fraction was evaporated under a stream of nitrogen, base treated 
with 1 N NaOH, and Folch partitioned as described previously (Kasperzyk et al. 
2004).  The Folch lower phase containing GA2 was evaporated under a stream 
of nitrogen and re-suspended in 4 mL CHCl3:CH3OH (2:1 by volume). 
 
Analysis of Lipids by HPTLC 
 All lipids were analyzed qualitatively by high-performance thin-layer 
chromatogram (HPTLC) according to previously described methods (Ando et al. 
1978; Seyfried et al. 1978; Macala et al. 1983; Kasperzyk et al. 2004).  To 
enhance precision, an internal standard (oleoyl alcohol) was added to the neutral 
and acidic lipid standards and samples as previously described (Macala et al. 
1983).  Purified lipid standards were either purchased from Matreya Inc. 
(Pleasant Gap, PA, USA), Sigma (St. Louis, MO, USA), or were a gift from Dr. 
Robert Yu (Medical College of Georgia, Augusta, GA, USA).  Lipids were spotted 
on 10 x 20 cm Silica gel 60 HPTLC plates (E. Merck, Darmstadt, Germany) using 
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a Camag Linomat V semi-automatic TLC spotter (Camag Scientific Inc., 
Wilmington, NC, USA).   
 For gangliosides and GA2, the HPTLC plates were developed by a single 
ascending run with CHCl3:CH3OH:dH2O (55:45:10 by volume for gangliosides 
and 65:35:8 by volume for GA2) containing 0.02% CaCl22H2O.  The plates were 
sprayed with either resorcinol-HCl or orcinol-H2SO4 reagent and heated on an 
aluminum block heater at 105°C for approximately 30 minutes to visualize 
gangliosides or GA2, respectively (Svennerholm 1957).   
 For neutral and acidic phospholipids, the plates were developed to a height of 
either 4.5 cm or 6 cm, respectively with chloroform: methanol: acetic acid: formic 
acid: water (35:15:6:2:1 by volume), and then both were developed to the top 
with hexanes: diisopropyl ether: acetic acid (65:35:2 by volume) as previously 
described (Macala et al. 1983; Seyfried et al. 1984).  Neutral and acidic 
phospholipids were visualized by charring with 3% cupric acetate in 8% 
phosphoric acid solution, followed by heating in an oven at 165°C for 7 minutes.   
 The percentage distribution and density of individual bands was determined 
as previously described (Kasperzyk et al. 2004).  Briefly, the HPTLC plates were 
scanned on a Personal Densitometer SI with ImageQuant software (Molecular 
Dynamics) or on a ScanMaker 4800 with ScanWizard5 V7.00 software 
(Microtek).  The total brain ganglioside distribution was normalized to 100% and 
the percentage distribution values were used to calculate sialic acid 
concentration of individual gangliosides as we previously described (Seyfried et 
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al. 1982).  The density value for GA2 was fit to a standard curve of known lipid 
concentration and used to calculate concentration.  For the neutral and the acidic 
phospholipids, each lipid was normalized to an internal standard (oleoyl alcohol) 
and its concentration was quantified using a standard curve of each respective 
lipid. All brain lipid concentrations are expressed as mg/100 mg dry weight.   
 
Sialidase Assay 
 The brain sialidase activity was measured as previously described 
(Hasegawa et al. 2001).  Briefly, tissue homogenates were incubated with 30 
nmol of the synthetic substrate 4-methylumbelliferone-neuraminic acid (4-MU-
NeuAc) (Sigma), 0.2 mg of bovine serum albumin, and 10 mmol of sodium 
acetate buffer at 37°C for 2 hours.  The sialidase activity towards 4-MU-NeuAc 
was measured spectrofluorometrically by the 4-methylumbelliferone release at 
excitation 365 nm and emission 450 nm (Hasegawa et al. 2001).  
 
Statistical Analysis 
 All data were analyzed by the unpaired Student’s t-Test to calculate 
statistical significance between the control (saline-injected) and the NB-DGJ 
treated Hexb -/- mice at p-5 using Statview 5.0 software.  
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RESULTS 
 
GM2 Accumulation Commences as Early as Postnatal Day 2 in Sandhoff 
Disease Mice 
 The content of total brain gangliosides and GM2 increased by about 2-fold 
from p-2 to p-5 in the Hexb -/- mice (Figure 9 and Table 1).  This indicates that 
GM2 accumulates rapidly during early postnatal brain development in the Hexb -
/- mice. 
 
Inhibition of Ganglioside Biosynthesis had no Significant Effect on Body or Brain 
Weights in Neonatal Sandhoff Disease Mice 
NB-DGJ treatment had no significant effect on body or brain weights in 
Hexb -/- mice (Table 1).  Brain water content, a sensitive indicator of mouse CNS 
maturation (Seyfried et al. 1978, 1979), was also similar in the saline-injected 
Hexb +/- and Hexb -/- mice and in the NB-DGJ-treated mice Hexb -/- mice (Table 
1).   
 
NB-DGJ Treatment Reduced Total Brain Ganglioside and GM2 Concentration in 
Neonatal Sandhoff Disease Mice 
 Our results also showed that four daily NB-DGJ injections (600 mg/kg) 
from p-2 to p-5 significantly reduced total brain ganglioside concentration while 
completely preventing GM2 accumulation (Table 1 and Figure 9).  In addition to 
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GM2, NB-DGJ also significantly reduced the concentration of GD1a, GD1b, and 
GT1b, and GQ1b in the Hexb -/- mice (Figure 10 and Table 2).  These findings 
indicate that NB-DGJ reduces gangliosides in both the “a” and “b“ metabolic 
pathways, as predicted (see Figure 7). 
 
Substrate Reduction Therapy did not Affect the Qualitative or Quantitative 
Distribution of Neutral or Acidic Lipids in Neonatal Sandhoff Disease Mice 
 The qualitative distribution of the neutral and acidic brain lipids in the 
control and the NB-DGJ-treated Hexb -/- mice is shown in Figures 11 and 12, 
respectively.  No differences were observed between the control and the NB-
DGJ-treated Hexb -/- mice for the distribution or content of the major neutral 
lipids (cholesterol, ceramide, phosphatidylethanolamine, phosphatidylcholine, 
sphingomyelin) or acidic phospholipids (cardiolipin, phosphatidylserine, 
phosphatidylinositol) (Table 3). Cerebrosides and sulfatides, myelin enriched 
glycolipids, were undetectable in the Hexb -/- mice (Figures 11 and 12).  These 
findings are consistent with the absence of myelin at this neonatal age (Seyfried 
and Yu 1980; Kasperzyk et al. 2004; Kasperzyk et al. 2005).  With the exception 
of GA2, no other neutral glycolipids, e.g., lactosylceramide, trihexosylceramide, 
globotriaosylceramide, or globoside were detected in the CNS of the Hexb -/- 
mice.  NB-DGJ treatment also had no significant effect on the content or 
distribution of any of the major brain neutral lipids including GA2 (Table 4). 
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Sialidase Enzymatic Activity was Slightly but Significantly Elevated in the NB-
DGJ Treated Neonatal Sandhoff Disease Mice 
 The absence of an effect on GA2 content is surprising since GA2 is 
derived from GM2, which was reduced by NB-DGJ.  We found that NB-DGJ 
caused a slight but significant elevation in brain sialidase activity (Table 4).  
These findings indicate that NB-DGJ, at 600 mg/kg, largely affects ganglioside 
content and not that of other brain lipids. 
 
DISCUSSION 
 
There are currently no effective therapies for SD or other CNS GSL 
storage diseases.  Diagnosis of an infantile onset ganglioside storage disease 
(the commonest presentation of this disorder) ultimately results in premature 
death.  Our objective was to determine if NB-DGJ might be an effective early 
intervention therapy for SD.  The idea is that if ganglioside biosynthesis can be 
reduced, ganglioside accumulation and pathogenesis may be delayed.  Although 
the imino sugar NB-DNJ (miglustat, Zavesca®) has been approved for the 
treatment of type I Gaucher disease and is under clinical evaluation for late onset 
Tay-Sachs disease and Niemann-Pick type C disease (Cox et al. 2000; Cox et al. 
2003; Lachmann 2003; Moyses 2003; Elstein et al. 2004; Pastores et al. 2005; 
Patterson et al. 2007). Zavesca® has significant adverse effects on body weight 
and GI tract function in both mice and in patients and may not be suitable for 
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early intervention therapy at doses high enough to achieve therapeutic levels in 
the CNS.  Recently, two patients with the infantile form of Tay-Sachs disease 
were treated with Zavesca® (Bembi et al. 2006).  Although both patients 
eventually died, one patient showed slower progression of neurological 
deterioration. Significant weight loss and diarrhea was observed in the treated 
patients, and as a result, the Zavesca® dosage was reduced.  Results from SRT 
studies using mice indicate that NB-DGJ is not associated with observable 
adverse effects and should permit greater dose escalation (Andersson et al. 
2004; Kasperzyk et al. 2004; Kasperzyk et al. 2005).  
Liu et al. reported a genetic approach to SRT in SD mice, where Hexb -/- 
mice were crossed with GalNAcT -/- mice (Liu et al. 1999).  The double knockout 
mice were unable to synthesize complex gangliosides, including GM2 and GA2.  
Although these mice did not accumulate GM2 and GA2 and had a significantly 
improved life-span, they developed neurological symptoms perhaps from the 
abnormal accumulation of the upstream precursors of GalNAcT (GM3 and GD3).  
This study demonstrated the effectiveness of SRT, but emphasized the importance 
of preventing secondary accumulation of other glycoconjugates from the treatment 
(Liu et al. 1999).  Our results, along with others show that SRT using NB-DGJ 
targets reduction in gangliosides without causing the accumulation from upstream 
precursors of GlcCerS (e.g. ceramide)(Andersson et al. 2004; Kasperzyk et al. 
2004).   
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Our results show for the first time that GM2 accumulates as early as p-2 in 
SD mice and that NB-DGJ significantly reduced total brain and GM2 ganglioside 
content when administered from p-2 to p-5 in Hexb -/- mice.  Furthermore, we 
show that NB-DGJ treatment reduced GM2 concentration to a greater extent in 
the neonatal than in the adult SD mice (Andersson et al. 2004).  We previously 
suggested that the reduction of brain GM1 content in NB-DGJ-treated GM1 
storage disease mice resulted from the inhibition of GM1 synthesis itself together 
with the inhibited synthesis of other more complex gangliosides that would be 
catabolized to GM1 (Kasperzyk et al. 2004).  Our results in the neonatal Hexb -/- 
mice support this hypothesis as NB-DGJ reduced not only GM2 content, but also 
that of other gangliosides synthesized through both the ‘a’ and ‘b’ metabolic 
pathways.   In neonatal brain, ganglioside biosynthesis occurs through the 
control of a complex of multiglycosyltransferases (Roseman 1970; Caputto et al. 
1974; Giraudo and Maccioni 2003). This process involves the synthesis of each 
ganglioside species on its own microsomal assembly where each metabolic 
intermediate becomes the substrate for the next biosynthetic reaction (Caputto et 
al. 1974; Giraudo and Maccioni 2003).  These findings suggest that NB-DGJ may 
be more effective at younger ages when GSL synthesis and turnover rates are 
more rapid than at older ages when these rates are much slower.   
We also found no adverse effects of NB-DGJ treatment on brain or body 
weights or on lipid composition in the neonatal SD mice.   NB-DGJ treatment did 
not alter brain maturation in contrast to mice with complete knockout of GlcCerS, 
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which did alter maturation (Jennemann et al. 2005).  These neonatal mice would 
be comparable to pre-natal humans as they precede myelination and cerebellar 
development (Verbitskaya 1969; Seyfried and Yu 1980; Seyfried et al. 1983; Morell 
and Quarles 1999).   These observations support previous studies in normal 
embryonic mice and in neonatal GM1 gangliosidosis mice treated with NB-DGJ 
(Brigande et al. 1998; Kasperzyk et al. 2004), suggesting that NB-DGJ may be an 
effective early intervention therapy for SD and possibly other ganglioside storage 
diseases. 
In addition to GM2, GA2 was also significantly elevated in the SD mouse 
brain.  Although the drug reduced brain GM2 content, it had no effect on GA2 
content.  We recently suggested that NB-DGJ might enhance a mouse brain 
sialidase to form GA1 from GM1 in a GM1 gangliosidoses mutant mouse 
(Kasperzyk et al. 2004).  In contrast to human brain sialidase, mouse brain 
sialidase can hydrolyze the internal sialic acid of GM1 and GM2 gangliosides 
(Sango et al. 1995; Phaneuf et al. 1996; Hahn et al. 1997; Matsuda et al. 1997).   It 
is possible that enhanced sialidase from NB-DGJ treatment might mask a potential 
reduction in GA2.  It was also recently shown that NB-DGJ could enhance the 
activity of a mutant lysosomal enzyme through chaperone effects (Tominaga et al. 
2001; Matsuda et al. 2003).  Our results support this contention.  Therefore, the 
slight, but significant increase in brain sialidase activity in our NB-DGJ treated mice 
may contribute to the unchanged GA2 levels during these neonatal ages.  This 
 38 
may not be a problem in SD patients, as hydrolysis of the GM2 sialic acid is much 
less for the human sialidase than for the mouse sialidase (Sango et al. 1995). 
Our results suggest that NB-DGJ largely targets ganglioside biosynthesis 
and does not noticeably alter other brain lipids in the neonatal SD mice.  A recent 
study showed that the content and synthesis of phosphatidylcholine and 
phosphatidylethanolamine was decreased in embryonic and adult SD mice 
suggesting that phospholipid alterations precede neurodegeneration associated 
with GSL accumulation in this model (Buccoliero et al. 2004).  However, we found 
no alterations in these phospholipids in the SD mice at neonatal ages.  We do not 
exclude the possibility that ganglioside GM2 or GA2 storage might secondarily 
influence phospholipid content in adult SD mice as previously reported for myelin 
lipids in the human GM2 gangliosidoses (Sandhoff et al. 1971; Gravel et al. 1995).  
Our results show that GSL accumulation begins at early neonatal ages in 
the SD mouse brain and that NB-DGJ treatment is effective in reducing total brain 
ganglioside and GM2 content.  As these reductions occurred in SD brains with little 
or no residual Hexb activity, it is possible that SRT would be more effective in 
reducing GM2 storage in diseased brains where some residual enzyme activity is 
present.  NB-DGJ treatment was not associated with any adverse effects in brain 
weight, body weight, or other lipid abnormalities in SD mice.  Based on our 
previous findings, continuous treatment with NB-DGJ may be necessary for 
efficacy (Kasperzyk et al. 2004).  This may involve daily infusions or injections 
during younger ages and then dietary supplementation at older ages as previously 
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described (Andersson et al. 2004).  Our findings suggest that NB-DGJ may be an 
effective early intervention therapy for Sandhoff disease and other GM2 
gangliosidoses.   
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Figure 6.  Substrate Reduction Therapy (SRT) Schematic.  GSL metabolism in, 
a) a normal person,  b)  a ganglioside storage disorder patient, and c)  an 
affected patient treated with SRT.  Adapted from the National Tay-Sachs and 
Allied Disease Association  
http://www.ntsad.org. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substrate Reduction Therapy
GSL Biosynthesis
GSL Degradation
 
 42 
Figure 7.  Influence of NB-DGJ on GSL biosynthesis in neonatal mice.  NB-DGJ  
inhibits GlcCerS, the enzyme that catalyzes the first step in GSL biosynthesis.  
GalCer, galactosylceramide; GlcCerS, glucosylceramide synthase; GlcCer, 
glucosylceramide; LacCer, lactosylceramide; the ‘a’ and the ‘b’ ganglioside 
metabolic pathways. 
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Figure 8.  The Imino Sugars N-butyldeoxynojirimycin (NB-DNJ, miglustat, 
Zavesca) and N-butyldeoxygalactonojirimycin (NB-DGJ).   The structure of 
these two imino sugars differ in the orientation of the hydroxyl group on carbon 4. 
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Figure 9.   Increase of total brain ganglioside and GM2 content between 
postnatal day 2 (p-2) and p-5 in saline control (C) or NB-DGJ (T) treated Hexb -/- 
mice.  Values represent mean + SEM.  The number of independent mice 
analyzed was 4-12 per group.  The asterisks indicate that the values are 
significantly different at P < 0.01. 
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Table 1:  Brain Ganglioside Content in Neonatal Hexb MiceTreated with NB-DGJ 
a
NB-DGJ 
Strain Age (mg/kg body wt) Nb
Hexb -/- p-2 0 4 1.5 + 0.1 104.1 + 4.4 86.77 + 0.05 41 + 3  295 + 15   
Hexb +/- p-5 0 3 2.9 + 0.4 190.4 + 13.3 87.30 + 0.06 99 + 11 406 + 19
Hexb -/- p-5 0 12 2.9 + 0.2 174.0 + 5.3 87.19 + 0.06 88 + 4 395 + 8
600 8 2.8 + 0.1 169.2 + 3.0 87.01 + 0.12 67 + 2 ** 304 + 8 **
b  N, the number of independent mice analyzed.
determined by the two-tailed test.
(µg/100 mg dry wt)
Body weight Brain weight Water Content
The asterisks indicate that the value is significantly different from that of the untreated  Hexb -/- (p-5) mice at  **P< 0.01 as
a  
Values represent the mean + SEM.
(g) (mg) (%) (µg/whole brain)
Ganglioside Sialic Acid
Content Concentration
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Figure 10.  HPTLC of brain gangliosides in neonatal (p-5) Hexb +/-  and Hexb -/- 
mice that were treated with saline (C) or NB-DGJ (T) from p-2 to p-5.  The 
amount of ganglioside sialic acid spotted per lane was equivalent to 
approximately 1.2 mg brain dry weight.  The plate was developed by a single 
ascending run with chloroform: methanol: water (55:45:10 by volume) containing 
0.02% calcium chloride.  The bands were visualized with the resorcinol-HCl 
spray. 
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Table 2.  Brain Ganglioside Distribution in Neonatal Hexb MiceTreated with NB-DGJa
NB-DGJ
Strain Age (mg/kg body wt) Nb
Hexb -/- p-2 0 4 10.0 + 0.9  11.1 + 0.8  8.7 + 1.0  92.5 + 4.5  14.6 + 0.9 19.4 + 1.4 110.2 + 6.5  28.2 + 2.6
Hexb +/- p-5 0 3 - 16.7 + 1.5 6.6 + 0.2 167.3 + 11.4 16.0 + 0.5 21.5 + 1.0 143.1 + 5.3 34.5 + 1.2
Hexb -/- p-5 0 12 13.5 + 0.6 17.0 + 0.9 6.1 + 0.4 156.8 + 3.1 16.9 + 0.6 21.8 + 0.8 133.7 + 3.2 29.5 + 1.2
600 8 5.8 + 0.3 ** 18.6 + 1.2  4.1 + 0.5 ** 117.4 + 3.1 ** 13.9 + 0.5 ** 16.6 + 0.6 ** 103.2 + 2.9 ** 24.8 + 1.3 *
a
 Values represent the mean + SEM.
b   N, the number of independent samples analyzed.
c
 Determined from densitometric scanning of HPTLC as shown in Fig 10.
Concentration (µg sialic acid / 100 mg dry weight)c
GQ1bGM2 GT1bGT1a/LD1GM1 GD3 GD1a GD1b
The asterisks indicate that the value is significantly different from that of the untreated Hexb -/- (p-5) mice at *P< 0.05 and at **P< 0.01 as determied by the two-tailed test.
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Figure 11.  HPTLC of brain neutral lipids in neonatal (p-5) Hexb +/-  and Hexb -/- 
mice that were treated with saline (C) or NB-DGJ (T) from p-2 to p-5.  The 
amount of neutral lipids spotted per lane was equivalent to approximately 200 µg 
brain dry weight.  The plate was developed to a height of 4.5 cm with chloroform: 
methanol: acetic acid: formic acid: water (35:15:6:2:1 by volume), then developed 
to the top with hexanes: diisopropyl ether: acetic acid (65:35:2 by volume).  The 
bands were visualized by charring with 3% cupric acetate in 8% phosphoric acid 
solution.  CE, cholesterol esters; TG, triglycerides; IS, internal standard; C, 
cholesterol; CM, ceramide; CB, cerebroside (doublet); PE, 
phosphatidylethanolamine; PC, phosphatidlycholine; SM, sphingomyelin. 
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Figure 12.  HPTLC of brain acidic lipids in neonatal (p-5) Hexb +/-  and Hexb -/- 
mice that were treated with saline (C) or NB-DGJ (T) from p-2 to p-5.  The 
amount of acidic lipids spotted per lane was equivalent to approximately 300 µg 
brain dry weight.  The plate was developed to a height of 6 cm with chloroform: 
methanol: acetic acid: formic acid: water (35:15:6:2:1 by volume), then developed 
to the top with hexanes: diisopropyl ether: acetic acid (65:35:2 by volume).  The 
bands were visualized by charring with 3% cupric acetate in 8% phosphoric acid 
solution.  FA, fatty acids; IS, internal standard; CL, cardiolipin; PA, phosphatidic 
acid; Sulf, sulfatides (doublet); PS, phosphatidylserine; PI, phosphatidyinositol. 
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Table 3:  Total Lipid Distribution in Neonatal Hexb Mice Treated with NB-DGJa
Lipids
NB-DGJ (mg/kg body wt) 0 0 600
Neutral lipidsb
Cc 2079 + 28 2221 + 102 2160 + 64
CM 86 + 4 86 + 7 115 + 8
PE 2279 + 61 2587 + 142 2388 + 91
PC 2785 + 47 2961 + 101 2889 + 98
SM 254 + 24 336 + 7 374 + 19
Acidic lipids
CL 354 + 32 400 + 14 391 + 26
PS 1564 + 53 1592 + 36 1748 + 122
PI 777 + 31 782 + 31 846 + 59
a   Values (µg / 100 mg dry weight) represent mean + SEM, where 3 independent samples
   were analyzed per group.
b   Determined from densitometric scanning of HPTLC as shown in Fig 11 and 12.
c  Lipid abbreviations are as described in Fig 11 and 12.
Hexb -/-Hexb +/-
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Table 4:  GA2 Concentration and Sialidase Activity in Neonatal Hexb -/- Mice Treated with NB-DGJa
 NB-DGJ 
Strain (mg/kg body wt)
Hexb -/- 0 264 + 8 6.9 + 0.1  
 600 253 + 5 7.4 + 0.2 *  
a   Values represent mean + SEM, where 3-11 independent samples were analyzed per group.
The asterisks indicate that the value is significantly different from that of the untreated Hexb -/- mice at *P< 0.05 
as determied by the two-tailed test.
GA2 Concentration Sialidase Activity
(µg / 100 mg dry weight) (nmol/mg protein/hr)
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CHAPTER THREE 
Neural Stem Cell Transplantation Reduces Brain GM2 and GA2 Content in a 
Mouse Model of Sandhoff Disease 
 
INTRODUCTION 
 
Cross-Correctional Therapy 
Lysosomal enzymes are synthesized and processed in the endoplasmic 
reticulum, where they acquire mannose-6-phosphate (M6P) residues (Figure 13).  
The M6P residues act as high-affinity ligands for binding to the M6P receptors in 
the Golgi.  The ligand-receptor complex can target the enzymes to the acidic 
lysosomes, where the acidic pH environment cleaves the M6P ligand.  In 
addition, M6P-lysosomal enzymes can be released by the cell, in which M6P 
receptors on the plasma membrane of a neighboring cell can uptake the 
lysosomal enzyme, thereby cross-correcting the cell (Neufeld 1973; Kornfeld 
1992; Gieselmann et al. 2003).  It is this cross-correction mechanism, where a 
normal cell can provide a source of functional enzyme for an affected cell, that 
underlies the rationale for using neural stem cells as a possible cell-based 
therapy for LSDs (Gieselmann et al. 2003). 
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Stem Cell Therapy 
The fundamental properties of neural stem cells (NSCs) are its ability to 
self-renew, differentiate, and migrate (Alvarez-Buylla and Temple 1998; Gage et 
al. 1998; Imitola 2007).  Self-renewal is the ability of a single stem cell to 
generate daughter cells that have identical properties, from generation to 
generation. NSCs can differentiate or remain multipotent where they give rise to 
the three different cell types in the CNS:  neurons, oligodendrocytes, and 
astrocytes.  Finally, NSCs have the ability to migrate to injury sites in the CNS 
(Imitola 2007).  These properties not only define NSCs, but also suggest 
potential for cell-mediated CNS therapy (Dobrenis 2004). 
Previous work has shown that engineered CNS progenitor cells can cross-
correct the deficient lysosomal enzyme in TSD fibroblasts (Lacorazza et al. 
1996). The authors also showed that these progenitor cells increased lysosomal 
enzyme in normal mice, suggesting that NSC transplantation could be a potential 
therapy for lysosomal storage diseases (Lacorazza et al. 1996).  Furthermore, 
NSC therapy is an appealing approach for neurodegenerative diseases because 
it can provide a source of cell replacement for dead or dying neurons and glial 
cells (Snyder et al. 1995; Flax et al. 1998; Yandava et al. 1999; Gage 2000).  
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 In this study, I evaluated the efficacy of NSC therapy using both murine 
NSCs and the NIH-derived human NSCs at neonatal ages in a mouse model for 
SD.  Our results show that NSCs engrafted and disseminated widely throughout 
the SD mouse cortex.  Following NSC transplantation, total hexosaminidase 
activity was increased and GM2 and GA2 are significantly reduced in the treated 
SD mice.  Furthermore, NSC therapy increased survival in the SD mice.  These 
results suggest that NSC therapy at neonatal ages may be an effective early 
intervention therapy for GM2 gangliosidoses. 
 
MATERIALS AND METHODS 
 
Mice 
 SD (Hexb -/-) mice were used for this study and are described in Chapter 
2.  
  
Stem Cell Cultures 
  The murine NSCs (mNSCs) and the human NSCs (hNSCs) were provided 
by Drs. Jean-Pyo Lee and Evan Snyder from the Burnham Institute for Medical 
Research (LaJolla, CA).  The stem cells were prepared according to their 
previously published methods (Lee et al. 2007).  
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Transplantation 
 Neonatal (p-1) SD mice were cryoanesthetized and held to a non-heat 
conducting transilluminator.  Using a glass micropipette, 2 µL of NSCs (5 x 104 
cells / µL in PBS with 0.05% trypan blue) were injected per ventricle.  Pups were 
returned to the dam until weaning.  Only well-transplanted pups, as defined with 
extensive distribution of cells throughout the ventricular system and limited to 
only the ventricular system, were used in this study.  The brains were collected at 
p-30.  The NSC transplantation procedure was done by Dr. Jean-Pyo Lee at the 
Burmham Institute for Medical Research as part of our collaborative study.   
 
Histology 
 Mouse brains were fixed with 4% paraformaldehyde and frozen in OCT 
embedding media at -80°C.  β-galactosidase in the mNSCs (from lacZ reporter) 
allowed identification of the donor-derived cells by 5-bromo-4-chloro-3-indolyl-β-
D-galactoside (Xgal) histochemistry in 20 µm serial coronal cryosections as 
previously described by our collaborator (Lee et al. 2007).  These histological 
sections were provided by Dr. Jean-Pyo Lee. 
 
β-Hexosaminidase Assay 
 Total β-Hexosaminidase activity was determined using a modification of 
the Galjaard procedure, as previously described (Galjaard 1980; Hauser et al. 
2004; Denny et al. 2006).  Tissue homogenates were centrifuged for 5 minutes at 
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2000 g and aliquots from the supernatant were analyzed.  40 µl aliquots were 
then added in duplicate to a BD Falcon 96-well micro-plate (ThermoFisher 
Scientific, Waltham, MA) on ice.  A standard curved of 4-methylumbelliferone 
(Sigma, St. Louis, MO) was also plated.   20 µl of 1 mM 4-methylumbelliferyl-N-
Acetyl-β-D-glucosaminide (4-MAG) (Sigma, St. Louis, MO) was then added to 
each tissue aliquot and standard.  4-MAG is a synthetic fluorogenic substrate, 
specific for β-Hexosaminidase.  The plate was incubated at 37°C for 30 minutes 
followed by the addition of 200 µl 0.5 M Na-carbonate stopping buffer (pH 10.7).  
Total β-Hexosaminidase activity was determined by measuring the release of 4-
methylumbelliferone at excitation 460 nm, emission 360 nm on a SpectraMax M5 
plate reader (Molecular Devices, Sunnyvale, CA).  Total protein concentration 
was determined using Bio-Rad acid dye solution (Bio-Rad, Hercules, CA) 
following the manufacturer’s standard micro-titer plate protocol, based on the 
method of Bradford (Bradford 1976).  The dye reagent was made by diluting 1 
part dye concentrate with 4 parts dH2O.  10 µL of diluted cell extracts 
(supernatants) and protein micro-standards (Sigma, St. Louis, MO) were added 
in duplicate to a 96 well plate.  200 µL of diluted dye reagent was added to each 
sample and standard.  The plates were incubated at room temperature for 15 
minutes and read at 595nm on a SpectraMax M5 plate reader (Molecular 
Devices, Sunnyvale, CA).  Total β-Hexosaminidase activity is expressed as 
nmol/mg protein / hr. 
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Isolation and Purification of Glycosphingolipids 
  GSLs were isolated and purified using the described methods in Chapter 2. 
 
Analysis of Glycosphingolipids by HPTLC 
 GSLs were analyzed by HPTLC as previously described in Chapter 2. 
 
Statistical Analysis 
 Data were analyzed by the unpaired Student’s t-Test to calculate 
statistical significance between the untreated and the NSC transplanted Hexb -/- 
mice at p-30 using Statview 5.0 software.  In addition, survival was presented 
using the Kaplan-Meier plot and significance was calculated using the log-rank 
test. 
  
RESULTS 
 
Stem Cells Engraft and Disseminate Widely Throughout the Cortex in Sandhoff 
Disease Mice 
 Hexb -/- mice were injected with murine NSCs (mNSCs) at postnatal day 1 
(p-1).  The mNSC distribution was visualized by Xgal staining of β-galactosidase.  
After mNSC implantation into the neonatal cerebral ventricles, mNSCs fill the 
ventricular cavity and at p-21, donor-derived cells were evident throughout the 
forebrain, with consistent staining in the cortical and subcortical regions (Lee et 
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al. 2007) (Figure 14).  This suggests that mNSCs have the ability to engraft and 
migrate throughout the CNS.   
 
β-Hexosaminidase Enzymatic Activity is Increased Following Stem Cell 
Transplantation 
It was previously shown that NSCs express normal levels of β-
Hexosamindase and that NSCs were able to cross-correct the enzymatic 
deficiency in TSD in vitro (Lacorazza et al. 1996; Flax et al. 1998).  In this study, 
we found that mNSCs transplanted into the CNS of Hexb -/- mice increased total 
β-Hexosaminidase activity by 2-3 fold (Figure 15).  The non-treated Hexb -/- mice 
express about 2% of wildtype levels of total β-Hexosaminidase activity, stemming 
from β-Hexosaminidase S (αα).   These results suggest that the mNSCs may 
compensate for the β-Hexosaminidase deficiencies by producing the missing 
enzyme and cross-correcting host cells.   
 
GM2 and GA2 are Reduced in the Cortex of NSC Transplanted Sandhoff 
Disease Mice  
 Cross-correction in the NSC-transplanted Hexb -/- mice was further 
assessed by analyzing the impact of NSCs on GSL storage in the CNS.  Our 
results showed that neonatal transplantation of mNSCs in Hexb  -/- mice 
significantly reduced cortical GM2 distribution and concentration at p-30 (Figures 
16A and 16B).   In addition, GA2 distribution and concentration was also 
 65 
significantly reduced (Figures 17A and 17B).  Furthermore, human NSCs 
(hNSCs) derived from human embryonic stem cells (hESCs) (NIH line WA-09) 
and maintained in feeder-free culture was also transplanted into the neonatal 
Hexb -/- mice and analyzed at p-30.  Our results show that hNSCs also reduce 
GM2 and GA2 in the cortex of transplanted Hexb -/- mice (Figure 18A and 18B).  
This suggests that both mNSCs and hNSCs are capable of cross-correction and 
reducing GSL storage in the CNS of SD mice.   
 
Neural Stem Cell Transplantation in Sandhoff Disease Mice Increased Survival 
 Hexb -/- mice begin to display motor difficulties around 90 days of age and 
become moribund around 120 days of age (Sango et al. 1995; Andersson et al. 
2004; Denny et al. 2006).  In our study, we evaluated the influence of mNSCs on 
survival in neonatal Hexb -/- mice. The untreated Hexb -/- mice succumbed to the 
disease between 115-130 days of age.  Our results show that survival in the 
mNSC-transplanted Hexb -/- mice was increased up to 170 days of age, 
corresponding to a 70% increase in longevity (Lee et al. 2007) (Figure 19).  
These results suggest that mNSC transplantation significantly increases survival 
in Hexb -/- mice and could be a potential early-intervention therapy for SD. 
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DISCUSSION 
Currently, there are no effective therapies for SD or other CNS GSL 
storage disorders. Our objective was to determine if NSCs might be an effective 
early intervention therapy for SD.  NSC therapy has great potential for success in 
SD.  The normal enzyme released by the NSCs can be taken up by adjacent 
cells via the M6P receptors, thereby cross-correcting the cell and reducing GSL 
storage (Lacorazza et al. 1996; Flax et al. 1998).  Additionally, NSCs have the 
ability to differentiate into all three cell-types of the CNS (neurons, 
oligodendrocytes, and astrocytes) and has the potential to replace dead or dying 
neurons and glial cells in neurodegenerative diseases (Snyder et al. 1995; Flax 
et al. 1998; Yandava et al. 1999; Gage 2000). 
Our results show that mNSCs engraft and disseminate widely throughout 
the cortex in neonatal Hexb -/- mice.  β-Hexosaminidase activity was significantly 
elevated in the mNSC transplanted SD mice.  This results in significant 
reductions of GM2 and GA2 in both the mNSC and the hNSC transplanted Hexb 
-/- mice.  Furthermore, we show that neonatal mNSC transplantation significantly 
increases survival in the SD mice.  Our findings suggest that NSC therapy may 
be an effective early intervention therapy for Sandhoff disease and other GM2 
gangliosidoses.   
Although NSC transplantation did not provide a permanent treatment or 
cure for the SD mouse, this study provided proof-of-concept to demonstrate that 
NSCs can cross-correct the biochemical deficiency in vivo and showed that cells 
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derived from hESCs could be used in an animal model of a degenerative 
disease.  In addition, SD also affects the brainstem, spinal cord, and to a lesser 
extent the periphery.  It is likely that intracranial transplantation needs to be 
combined with additional strategies to reach these areas.   Our results suggest 
that neonatal NSC transplantation provides a source of lysosomal enzyme and is 
capable of cross-correction in a mouse model of Sandhoff disease.   
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Figure 13.  Lysosomal Enzyme Processing.  Lysosomal enzymes (small black 
circles) are synthesized and processed in the endoplasmic reticulum (ER), where 
lysosomal enzymes acquire mannose-6-phosphate (M6P) residues (small pink 
circles).  The M6P residues act as high-affinity ligands for binding to the M6P 
receptors (orange semicircles) in the Golgi.  The ligand-receptor complex can 
target the enzymes to the acidic lysosomes, where the acidic pH environment 
cleaves the M6P ligand.  In addition, M6P-lysosomal enzymes can be released 
by the cell, in which M6P receptors (M6PR) on the plasma membrane of a 
neighboring cell can uptake the lysosomal enzyme, thereby cross-correcting the 
cell (Neufeld 1973; Kornfeld 1992; Gieselmann et al. 2003). 
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Figure 14. Coronal sections of a p-2 (A) and a p-21 (B) SD mouse brain showing 
murine neural stem cells (mNSCs) stained for the β-galactosidase reporter gene 
(LacZ) (Lee et al. 2007).  The mice were transplanted (icv) at p-1 with mNSC 
clone C17.2 cells expressing LacZ.  The NSCs were primarily localized to the 
ventricles at p-2, but were widely disseminated throughout the cerebral cortex at 
p-21.  The p-2 brain was enlarged 3.5X for comparison with the p-21 brain.  Bar = 
1 mm.  
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Figure 15.  Influence of mNSCs on β-Hexosaminidase activity in cortical Hexb -/- 
mice that were either untreated (C) or transplanted with mNSCs (mTx) at p-1.   
Enzymatic activity was normalized to wildtype levels and is expressed as % of 
wildtype.   Values represent mean + SEM.  The number of independent mice 
analyzed was 4-5 per group. The asterisk indicate that the values are 
significantly different at P < 0.01. 
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Figure 16.  Influence of mNSCs on cortical ganglioside distribution (A) and GM2 
content (B) in 30-day Hexb +/- and Hexb -/- mice that were either untreated (C) 
or transplanted with mNSCs (mTx) at p-1 (icv).  The amount of ganglioside sialic 
acid spotted per lane was equivalent to approximately 1.0 mg tissue dry weight. 
The plate was developed by a single ascending run with chloroform: methanol: 
water (55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray.  Values are expressed as means + SEM 
where 4-5 independent cortex samples were analyzed per group.  The asterisks 
indicates that the value of the treated group differs from the control group at P < 
0.01 as determined by the two-tailed t-test. 
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Figure 17.  Influence of mNSCs on cortical GA2 distribution (A) and GA2 content 
(B) in 30-day Hexb +/- and Hexb -/- mice that were either untreated (C) or 
transplanted with mNSCs (mTx) at p-1 (icv).  The amount of sample spotted per 
lane was equivalent to approximately 0.4 mg tissue dry weight.  A GA2 standard 
curve is also shown.  The plate was developed by a single ascending run with 
chloroform: methanol: water (65:35:8 by volume) containing 0.02% calcium 
chloride.  The bands were visualized with the orcinol-H2SO4 spray.  Values are 
expressed as means + SEM where 4-5 independent cortex samples were 
analyzed per group.  The asterisk indicates that the value of the treated group 
differs from the control group at P < 0.05 as determined by the two-tailed t-test. 
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Figure 18.  Influence of NSCs on cortical GM2 content (A) and GA2 content (B) 
in 30-day Hexb +/- and Hexb -/- mice that were either untreated (C) or 
transplanted with mNSCs (mTx) or human NSCs (hTx) at p-1 (icv).  Values are 
expressed as means + SEM where 4-5 independent cortex samples were 
analyzed per group.  The asterisks indicates that the value of the treated group 
differs from the control group at * P < 0.05, ** P < 0.01 as determined by the two-
tailed t-test. 
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Figure 19.  Influence of mNSCs on survival in Hexb -/- mice that were either 
untreated (C) or transplanted with mNSCs (mTx) at p-1 (icv) (Lee et al. 2007).  
Data was plotted using the Kaplan-Meier survival curve.  Survival in the mTx 
mice was significantly longer than in the untreated mice at P < 0.0001, according 
to the log-rank test.  The number of independent mice analyzed was 43-57 per 
group. 
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CHAPTER FOUR 
Complete Correction of Enzymatic Deficiency and Neurochemistry in the GM1 
Gangliosidosis Mouse Brain by Neonatal Adeno-Associated Virus-Mediated 
Gene Delivery 
 
INTRODUCTION 
 
Gene Therapy 
 Cross-correction is the basis for gene therapy for the treatment of LSDs 
(discussed in Chapter 3).  Gene therapy is an appealing approach for LSDs in 
that not all cells in the CNS have to be genetically modified to achieve 
therapeutic efficacy.  Infusion of adeno-associated virus (AAV) vectors into the 
brain lateral ventricles of neonatal mice has proven to be an effective approach 
to obtain widespread distribution of vector-transduced cells and lysosomal 
enzymes throughout the brain (Passini and Wolfe 2001; Passini et al. 2003; Rafi 
et al. 2005). The distribution of lysosomal enzyme results from its continued 
release from vector-transduced cells over long periods of time, diffusion in the 
brain parenchyma, axonal transport within neurons from the site of production, 
and through cerebrospinal fluid flow in the perivascular space of Virchow-Robin 
(Taylor and Wolfe 1997; Passini et al. 2002; Liu et al. 2005).   
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Adeno-Associated Viral Vectors 
 The adeno-associated virus (AAV) belongs to the dependovirus genus of 
the parvovirus family. The AAV with capsid is about 20-30 nm in size and its 
genome is about 4.7 kilobases in length (Davidson and Breakefield 2003; Ding et 
al. 2005).  There are approximately 12 AAV serotypes to date, and the AAV 
serotype 2 (AAV2) is the most studied and best characterized (Choi et al. 2005; 
Schmidt et al. 2008).    The AAV genome contains two proteins, rep and cap, 
which are required for replication and packaging (Figure 20).  In addition, flanking 
these viral genes are the inverted terminal repeats (ITR) at each end of the AAV 
single-stranded DNA genome (Ding et al. 2005).  AAV vectors can be engineered 
to replace the two viral genes with a transgene cassette between the ITRs, giving 
rise to recombinant AAV (rAAV) (Choi et al. 2005).  
 Five major steps are involved for AAV2 cell transduction and gene 
expression; (1) binding to cell-surface receptor, (2) endocytosis, (3) trafficking to 
the nucleus, (4) viral genome uncoating, and (5) transcription using the host 
machinery (Summerford and Samulski 1998; Buning et al. 2003; Choi et al. 2005; 
Ding et al. 2005) (Figure 21). The advantages of using AAV as a tool in gene 
therapy research lies on its ability to transduce both dividing and non-dividing 
cells, low toxicity with infection, and long, stable expression of the transgene 
(Choi et al. 2005).  In addition, rAAV vectors do not integrate into the host’s 
genome.  A disadvantage for using AAV in gene therapy is its relatively small 
packaging capacity, limited to about 4.5 kb. 
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 Viral vector-mediated gene delivery to the brain holds great potential for 
the treatment of LSDs as the genetic modification of small numbers of 
endogenous cells has proven to be sufficient to deliver corrective levels of 
enzyme to large regions of the CNS (Sands and Davidson 2006).  In this study, I 
investigated AAV-mediated gene therapy in neonatal GM1 gangliosidosis mice.   
 
  
MATERIALS AND METHODS 
 
Mice 
 The GM1 gangliosidosis (βgal -/-) mice were obtained from Dr. Kunihiko 
Suzuki (University of North Carolina, Chapel Hill, NC).  These mice were derived 
by homologous recombination and embryonic stem cell technology as previously 
described (Sango et al. 1995; Hahn et al. 1997). In addition, the C57BL/6 (WT) 
mice were used as wild-type controls.  This study was done in collaboration with 
Drs. Marike Broekman and Miguel Sena-Esteves at the Massachusetts General 
Hospital.  Therefore, the experimental protocol was approved by the Institutional 
Animal Care and Use Committee at the and followed guidelines set forth in the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
 
 85 
AAV Vector Design and Preparation 
   The AAV vector used in this study was derived as previously described by 
our collaborators (Broekman et al. 2006).  The AAV2 genome contains the 
murine lysosomal βgal cDNA under the transcriptional control of a hybrid CMV 
enhancer/chicken β-actin promotor and was packaged in an AAV1 capsid.  The 
AAV2/1 vector was prepared with a titer of 4.12 x 1013 genome copies per mL as 
previously described (Broekman et al. 2006).   
 
Transplantation 
 Neonatal (p-0) βgal -/- mice were cryoanesthetized and injected with 2 µL 
of viral vector into each cerebral lateral ventricle (icv) using a glass pipette.  Pups 
were returned to the dam until weaning.  AAV injections were performed by Dr. 
Marike Broekman at the Massachusetts General Hospital as part of our 
collaborative study. 
 
Tissue Preparation 
 The brains were harvested at p-90, or at 3 months post transplantation.  
The left hemisphere of the brain was embedded in tissue freezing medium 
(Triangle Biomedical Sciences, Durham, NC) and rapidly frozen in a 2-
methylbutane/dry-ice bath.  Consecutive 20 µm thick coronal cryosections were 
prepared and analyzed for X-gal staining.  The right hemisphere of the brain was 
rapidly frozen in the vapor phase of liquid nitrogen and cut into 50 µm sections.  
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Alternate sections were used for the βgal enzymatic assay and for the lipid 
analysis.    In addition, the cerebellum was analyzed as a single unit. 
 
 
Histology 
 β-galactosidase distribution was analyzed by Xgal staining as previously 
described (Broekman et al 2006).  
 
β-Galactosidase Assay 
 The β-galactosidase enzymatic assay was similar to the β-
Hexosaminidase Assay as described in Chapter 3.  Except for 4-
methylumbelliferyl-β-D-galactopyranoside (4-MUG) was used as the synthetic 
substrate.   
 
Isolation and Purification of Glycosphingolipids 
  GSLs were isolated and purified using the described methods in Chapter 2. 
 
Analysis of Glycosphingolipids by HPTLC 
 GSLs were analyzed by HPTLC as previously described in Chapter 2. 
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Statistical Analysis 
 All data were analyzed by one-way analysis of variance to calculate 
statistical significance between the untreated and the AAV-treated βgal -/- mice 
and the C57BL/6 wild-type control mice at p-90 using Statview 5.0 software.  
  
RESULTS 
 
β-Galactosidase was Distributed Throughout the Brain in GM1 Gangliosidosis 
Mice 
 The distribution of β-galactosidase (βgal) throughout the brain in AAV-
treated GM1 gangliosidosis (βgal -/-) mice, untreated βgal -/- mice, and in 
C57BL/6 wild-type (WT) mice was evaluated by staining histological sections with 
X-gal solution at pH 5.0 (Broekman et al. 2006) (Figure 22).  Intense βgal 
staining was observed in all regions of the brain in the AAV-treated βgal -/- mice.  
In contrast, X-gal staining was absent in the untreated βgal -/- mice and faint in 
the WT mice.  These results indicate that βgal distributes throughout the brain 
following AAV-treatment.   
 
AAV Treatment Significantly Elevated β-Galactosidase Activity in Brains of Adult 
GM1 Gangliosidosis Mice 
β-galactosidase enzymatic activity in the brain was quantified using the 
synthetic substrate 4-methylumbelliferyl-β-D-galactopyranoside (Figure 23A). 
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βgal activity in the AAV-treated βgal -/- mice was about 7- to 65-fold higher than 
in the WT controls.  In contrast, βgal activity in the untreated βgal -/- mice was 
only 1-4% of wild-type levels.  In addition, βgal activity was also measured in the 
liver (Figure 23B).   Our results show that AAV-treatment did not influence βgal 
activity in the liver. 
 
GM1 was Corrected and GA1 was Eliminated in the AAV-Treated GM1 
Gangliosidosis Mice 
 The effect of AAV-treatment on lysosomal storage in βgal -/- mice was 
quantified in region 4 of the brain (Table 5 and Figures 24 and 25) and in the 
cerebellum (Table 6 and Figure 26 and 27) by high-performance thin layer 
chromatography (HPTLC).  GM1 concentration in the forebrain of untreated βgal 
-/- mice was about 9-fold higher than in the WT control mice (Table 5 and Figure 
24).  AAV-treatment significantly reduced GM1 storage in the βgal -/- mice to 
wild-type levels.  In addition, AAV-treatment eliminated GA1 storage in the 
forebrain of the βgal -/- mice (Figure 25).  We also examined the cerebellum for 
lysosomal storage following AAV-treatment.  Our results show that AAV-
treatment also normalized GM1 storage and eliminated GA1 in the cerebellum of 
βgal -/- mice (Figures 26 and 27).   
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The Myelin-Enriched Lipids, Cerebrosides and Sulfatides were Corrected 
Following AAV-Treatment in GM1 Gangliosidosis Mice 
 The qualitative distribution of the neutral and acidic brain lipids in the AAV-
treated βgal -/- mice, the untreated βgal -/- mice, and in the WT control mice is 
shown in Figure 28.  No differences were observed between the untreated WT 
control and βgal -/- mice and the AAV-treated βgal -/- mice for the distribution or 
content of the major neutral lipids (cholesterol, ceramide, 
phosphatidylethanolamine, phosphatidylcholine, sphingomyelin) or acidic 
phospholipids (cardiolipin, phosphatidylserine, phosphatidylinositol).  
Cerebrosides and sulfatides, myelin enriched glycolipids, were significantly lower 
in the untreated βgal -/- mice compared to the WT control mice (Table 7 and 
Figure 28, arrows).  This finding is consistent with previous reports of 
hypomyelination in LSD animal models and in patients (Sandhoff et al. 1989; 
Kaye et al. 1992; Kroll et al. 1995; Folkerth et al. 2000; Denny et al. 2006, 
McNally et al. 2007).  Interestingly, AAV-treatment corrected the cerebrosides 
and sulfatides in the βgal -/- mice to the normal WT levels (Table 7).  Our results 
show that AAV-treatment corrected the myelin-enriched lipids, cerebrosides and 
sulfatides without a significant effect on the content or distribution of any of the 
major brain neutral or acidic lipids.   
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DISCUSSION 
 
 The biochemical defect in GM1 gangliosidosis has been known for many 
years, yet no effective treatment or therapies have been developed for the 
patient (Suzuki et al. 1995).  Several therapeutic approaches are being explored 
for GM1 gangliosidosis, to include substrate reduction therapy, chemical 
chaperone therapy, viral vector-mediated intravenous gene therapy, and 
transplantation of genetically modified hematopoetic stem cells (Matsuda et al. 
2003; Takaura et al. 2003; Kasperzyk et al. 2004; Sano et al. 2005; Suzuki et al. 
2007; Broekman et al. 2006).  Although these therapies showed significant 
reductions in the neurochemical storage, long-term management was not 
achieved.  Ganglioside accumulation commences early during embryonic and 
early neonatal periods in the infantile- and juvenile-onset forms of the GM1 
gangliosidoses, therefore, early intervention may be necessary for the effective 
management of disease (Suzuki et al. 1995; Takaura et al. 2003; Kasperzyk et 
al. 2004).   
 In this study, I evaluated the therapeutic potential of an AAV2/1 vector 
encoding the mouse lysosomal βgal injected into the cerebral lateral ventricles of 
neonatal GM1 gangliosidosis mice.  It was previously shown that this is an 
effective strategy to achieve widespread gene delivery to the brain and has been 
successful to prevent or reverse lysosomal storage in other mouse models of 
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LSDs to include mucopolysaccharidosis VII and globoid cell leukodystrophy, 
(Passini et al. 2003; Rafi et al. 2005).   
At 3 months of age, βgal was distributed throughout the brain and 
enzymatic activities were significantly elevated in the AAV-treated GM1 
gangliosidosis mice.  Although the βgal levels in the treated animals were many-
fold greater than what is seen in normal wild-type mice, AAV-treatment did not 
appear to cause any obvious neuroanatomical or behavioral abnormalities.    
Accumulation of GM1 in the brain of the GM1 gangliosidosis mice can be 
detected as early as postnatal day 5 and can reach levels that are 5-fold (µg 
sialic acid/100 mg dry weight) higher than normal by 3.5 months of age (Hauser 
et al. 2004; Kasperzyk et al. 2004).  In addition to GM1 storage, GA1 also 
accumulates in the brains of βgal -/- mice.  My results show that AAV-treatment 
normalized GM1 storage and eliminated GA1 in the brain of GM1 gangliosidosis 
mice.  Furthermore, the myelin-enriched lipids, cerebrosides and sulfatides were 
also normalized following AAV-treatment.  Together, our results suggest that 
neonatal AAV-treatment is effective in correcting the biochemical deficiency and 
normalizing the neurochemical accumulation in a mouse model of GM1 
gangliosidosis.  
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Figure 20. The AAV genome and the AAV vector carrying the mouse lysosomal 
acid β−gal cDNA under transcriptional control of a promotor (AAV-βgal).  Adapted 
from Korf (Korf 2006). 
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Figure 21. The Major Stages of AAV2 Transduction in a Cell; (1) the AAV2 
binding to a cell-surface receptor, (2) endocytosis,  (3) trafficking to the nucleus, 
(4) viral uncoating to release the genome, and (5) viral transcription using the 
host machinery.  Adapted from Ding et al. (Ding et al. 2005).    
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Figure 22.  Distribution of βgal in the brains of C57BL/6 wild-type (WT) and GM1 
gangliosidosis mice (βgal -/-) injected (icv) with AAV vector at p-0 and analyzed 
at p-90 by X-gal staining (Broekman et al. 2006).  Representative sections from 
regions 1-5 in (a) are shown in (b).  Bar = 1mm.  
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Figure 23. Influence of AAV-βgal on β-galactosidase activity in the brain (a) and 
liver (b) of βgal -/- mice that were injected (icv) with AAV-βgal (black bars) and in 
untreated B6 wild-type (WT) (open bars) and βgal -/- mice (KO) (gray bars).   
Enzymatic activity was measured in five regions (same as in Figure 22a) and the 
cerebellum. βgal activity is expressed in nmol/hour/mg protein and the values 
represent mean + SEM.  The number of independent mice analyzed was 3-7 per 
group.  
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Figure 24.  Influence of AAV-βgal on forebrain ganglioside distribution in brain 
region 4 (see Figure 22a) in 90-day wild-type C57BL/6 (WT) and βgal -/- mice 
that were either untreated (C) or injected with AAV-βgal (AAV) at p-0 (icv).   The 
amount of ganglioside sialic acid spotted per lane was equivalent to 
approximately 1.5 µg sialic acid. The plate was developed by a single ascending 
run with chloroform: methanol: water (55:45:10 by volume) containing 0.02% 
calcium chloride.  The bands were visualized with the resorcinol-HCl spray.  
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Figure 25. Influence of AAV-βgal on forebrain GA1 distribution in brain region 4 
(see Figure 22a) in 90-day C57BL/6 wild-type (WT) and βgal -/- mice that were 
either untreated (C) or injected with AAV-βgal (AAV) at p-0 (icv). The amount of 
sample spotted per lane was equivalent to approximately 0.2 mg tissue dry 
weight.  A GA1 standard curve is also shown.  The plate was developed by a 
single ascending run with chloroform: methanol: water (65:35:8 by volume) 
containing 0.02% calcium chloride.  The bands were visualized with the orcinol-
H2SO4 spray.  
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Figure 26. Influence of AAV-βgal on cerebellar ganglioside distribution in 90-day 
C57BL/6 wild-type (WT) and βgal -/- mice that were either untreated (C) or 
injected with AAV-βgal (AAV) at p-0 (icv).   The amount of ganglioside sialic acid 
spotted per lane was equivalent to approximately 1.5 µg sialic acid. The plate 
was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray.  
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Figure 27. Influence of AAV-βgal on cerebellar GA1 distribution in 90-day 
C57BL/6 wild-type (WT) and βgal -/- mice that were either untreated (C) or 
injected with AAV-βgal (AAV) at p-0 (icv). The amount of sample spotted per lane 
was equivalent to approximately 0.2 mg tissue dry weight.  A GA1 standard curve 
is also shown.  The plate was developed by a single ascending run with 
chloroform: methanol: water (65:35:8 by volume) containing 0.02% calcium 
chloride.  The bands were visualized with the orcinol-H2SO4 spray. 
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Figure 28.  HPTLC analysis of brain neutral and acidic lipids in C57BL/6 wild-type 
(WT) and βgal -/- mice (p-90) that were either untreated (C) or injected with AAV-
βgal (AAV) at p-0 (icv).  The amount of neutral and acidic lipids spotted per lane 
was equivalent to approximately 0.07 mg and 0.2 mg tissue dry weight, 
respectively.  The neutral and acidic HPTLC plates were developed to a height of 
4.5 cm and 6 cm, respectively with chloroform: methanol: acetic acid: formic acid: 
water (35:15:6:2:1 by vol).  The plates was then developed to the top with 
hexanes: diisopropyl ether: acetic acid (65:35:2 by vol).  The lipids were 
visualized by charring with 3% cupric acetate in 8% phosphoric acid solution. 
Cerebrosides and sulfatides are significantly reduced in the βgal -/- mice and 
AAV-βgal treatment restores their levels to normal WT levels (see arrows).  
Abbreviations: CE - Cholesterol Esters; TG – Triglycerides; IS – Internal 
standard; Chol – Cholesterol; Cer – Ceramide; CB – cerebrosides (doublet); PE 
– Phosphatidylethanolamine; PC – Phosphatidylcholine; SM – Sphingomyelin; 
FA – Fatty acids; CL – Cardiolipin; PA – Phosphatidic Acid; Sulf – Sulfatides 
(doublet); PS – Phosphatidylserine; PI – Phosphatidylinositol 
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Table 7: Effect of AAV Vector on Neutral and Acidic Forebrain Glycosphingolipids in Adult !gal Micea
  
Strain Treatment Nb
C57BL/6 - 3 2.7 + 0.1 0.81 + 0.14
!gal -/- - 3 1.6 + 0.2# 0.31 + 0.04#
!gal -/- AAV 7 3.0 + 0.3* 0.82 + 0.09*
a  
Values represent the mean + SEM.  The concentrations of cerebrosides and sulfatides are expressed as mg/100 mg dry weight.
b  
N, the number of independent mice analyzed.
#
 Indicates that the value is significantly different from that of the wildtype C57BL/6 mice at P < 0.05.
*Indicates that the value is significantly different from that of the !-gal -/- mice at P < 0.01.
Cerebrosides Sulfatides
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CHAPTER FIVE 
Neurochemical and Behavioral Improvement Following AAV-Mediated Gene 
Therapy in Adult GM1 Gangliosidosis Mice 
 
INTRODUCTION 
 
 Neonatal gene therapy was effective in reducing ganglioside accumulation 
in the GM1 gangliosidosis mice (Chapter 4).   However, these neonatal mice 
would be comparable to pre-natal humans as they precede myelination and 
cerebellar development (Verbitskaya 1969; Seyfried and Yu 1980; Seyfried et al. 
1983; Morell and Quarles 1999).  In this study, I investigated AAV-mediated gene 
therapy in adult GM1 gangliosidosis mice.  
 AAV-mediated gene therapy in adult mice has been shown to be effective 
in reducing CNS pathology and correcting motor deficits in several LSD mouse 
models to include, Sandhoff disease, mucopolysaccharidosis IIIB, Batten’s 
disease, Niemann-Pick type A, and globoid cell leukodystrophy (Dodge et al. 
2005; Rafi et al. 2005; Cachon-Gonzalez et al. 2006; Passini et al. 2006; Cearley 
and Wolfe 2007; Fu et al. 2007). In addition, AAV gene therapy increased 
survival by 150% in the Sandhoff disease mouse model (Cachon-Gonzalez et al. 
2006).  These remarkable results suggest that AAV-mediated gene therapy 
initiated at later ages may be a viable approach for treating patients.   
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 The primary target for AAV-mediated gene therapy in LSDs has been the 
striatum.  It has been shown that lysosomal enzymes secreted from genetically 
modified cells could be transported to distal sites in the brain via axonal transport 
(Passini et al. 2002). Based on this finding, we targeted the thalamus and the 
deep cerebellar nuclei to balance the minimal number of injections to obtain the 
maximal distribution of enzyme throughout the CNS.  The thalamus acts as a 
central processing unit of the brain as it receives inputs from many CNS regions 
and then relays information to the cerebral cortex (Steriade and Llinas 1988).  
The cerebellum controls motor coordination, fine motor control, and movement 
(Fine et al. 2002), therefore, the deep cerebellar nuclei was also targeted as the 
GM1 gangliosidosis mice display ataxia and disturbances in motor behavior 
(Ichinomiya et al. 2007).   
AAV-mediated gene therapy in adult GM1 gangliosidosis mice increasesd 
βgal activity and significantly reduced neurochemical storage in the CNS regions 
(cortex, brainstem, cerebellem, and spinal cord) analyzed.  In addition, motor 
coordination and locomotor activity was analyzed in the mice.  Although rotorod 
performance was not significantly improved, locomotor and rearing activity was 
greater in the AAV-treated animals.  These results suggest that AAV-mediated 
gene therapy may be an effective treatment for patients.   
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MATERIALS AND METHODS 
 
Mice 
 The GM1 gangliosidosis (βgal -/-) mice were obtained from Dr. Alessandra 
d’Azzo (St. Jude Children’s Research Hospital, Memphis, TN).  These mice were 
derived by homologous recombination and embryonic stem cell technology as 
previously described (Sango et al. 1995; Hahn et al. 1997).  These are the same 
mice used in the previous study (Chapter 4), but were obtained from a different 
source.  βgal -/- mice were derived from crosses of βgal +/- females with βgal -/- 
males and the genotypes of mice were determined by enzymatic activity as 
previously described (Hauser et al. 2004; Kasperzyk et al. 2004).  All mice were 
propagated in the Boston College Animal Care Facility and were housed in 
plastic cages with filter tops containing Sani-Chip bedding (P.J. Murphy Forest 
Products Corp., Montville, NJ).  All other conditions have been previously 
described (Kasperzyk et al. 2004).  The experimental protocol was carried out 
with ethical committee approval in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals and was approved by 
the Institutional Animal Care Committee.  
 
AAV Vector Design and Preparation 
   The AAV vector used in this study was described in Chapter 4. 
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AAV Injection 
 βgal -/- mice (60 days of age) were anesthetized and placed in a rodent 
stereotactic frame (Stoelting, Wood Dale, IL). The infusion system used in these 
experiments was assembled using a Harvard 22 syringe pump (Harvard 
Apparatus, Holliston, MA) to drive a gas-tight Hamilton Syringe (Hamilton, Reno, 
NV) attached to a 33-guage steel needle. One microliter of PBS (vehicle) or AAV 
encoding the mouse βgal (1 x 1013 genome copies / mL) was infused bilaterally 
into the thalamus (Th) or into the thalamus and cerebellum (Th+CB) at 0.2 µL per 
minute.  Burr holes were drilled over target sites and AAV vector or vehicle was 
delivered using coordinates relative to bregma in mm (Thalamus:  AP -2.0, ML + 
1.5, DV -2.5; Cerebellum:  AP -6.3, ML + 1.5, DV -2.0).  The wound was 
immediately closed using collodion (JT Baker, Inc, Phillipsburg NJ).  The mice 
were returned to their cages and monitored until they were fully active.  AAV 
injections were done at Boston College and were performed by Rena Baek and 
Dr. Miguel Sena-Esteves. 
 
Tissue Preparation 
 The brains were harvested at 1 and 4 months post transplantation.  The 
left hemisphere of the brain was embedded in tissue freezing medium (Triangle 
Biomedical Sciences, Durham, NC) and rapidly frozen in a 2-methylbutane/dry-
ice bath.  Consecutive 20 µm thick coronal cryosections were prepared and 
analyzed for X-gal staining.  The right hemisphere of the brain was grossly 
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dissected into the cortex, cerebellum, and brainstem and rapidly frozen on dry 
ice.  The right hemisphere was analyzed for βgal enzymatic activity and lipid 
analysis.  In addition, the spinal cord and grossly dissected into 0.5 cm sections.  
Alternating sections were collected and analyzed for GSL storage.  The values 
for the untreated and PBS-treated βgal -/- mice were indistinguishable from each 
other and as a result, were pooled together. 
 
 
β-Galactosidase Assay 
 The β-galactosidase enzymatic assay was described in Chapter 4. 
 
Isolation and Purification of Glycosphingolipids 
  GSLs were isolated and purified using the described methods in Chapter 2. 
 
Analysis of Glycosphingolipids by HPTLC 
 GSLs were analyzed by HPTLC as previously described in Chapter 2. 
 
Behavioral Testing 
ROTOROD 
A rotorod apparatus, consisting of a knurled dowel fixed 10 cm above 
bedding was used to measure motor coordination and balance as previously 
described (Denny et al. 2006).  After a 3-day pretrial training period, mice were 
assessed for motor behavior at 1, 2.5, and 4 months post transplantation.  Mice 
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were placed on the rotating dowel at speeds of 20, 40, and 60 rpm, indicating the 
start time for the trial.  A 30-second interval was allowed between the two trials at 
a given speed, and a 2-minute interval was allowed between different speeds.  
The maximum time allowed on the bar for each trial was 60 seconds.  The trial 
was terminated when the mouse fell off the bar or at 60 seconds.   
 
OPEN-FIELD TEST 
  Locomotor activity and rearing events in the mice were assessed using 
the SmartFrame Cage Rack System (Kinder Scientific, San Diego, CA).  Laser 
beams along the frame of the system track mouse movement in the cage with 
respect to location, distance, and rearing capabilities.  Mice were placed in the 
center of the open-field apparatus and behavior was measured for 5 minutes.  
The data was analyzed using the MotorMonitor software (Kinder Scientific, San 
Diego, CA).  Locomotor activity was measured as the distance traveled (in 
inches) and rearing events were measured as the number of times the mouse 
stood on its hind legs during the 5-minute period 
  
Statistical Analysis 
 All data were analyzed by one-way analysis of variance to calculate 
statistical significance between the untreated βgal -/- mice and the AAV-treated 
βgal -/- mice and the control βgal +/- mice using Statview 5.0 software.    
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RESULTS 
 
Adult AAV Treatment Significantly Elevated β-Galactosidase Activity in the CNS 
of GM1 Gangliosidosis Mice 
β-galactosidase (βgal) enzymatic activity in the CNS was quantified at 1 
month and 4 months post intracranial (ic) AAV injections (Figures 29 and 30, 
respectively).   At 90 days of age, or 1 month post ic injection, βgal activity in the 
AAV thalamic only (AAV-Th) and AAV in thalamic and cerebellar (AAV-Th+CB) 
treated βgal -/- mice was significantly elevated in the cortex and in the brainstem 
compared to the control βgal +/- mice (C) (Figure 29).  βgal activity in the 
cerebellum was further elevated following AAV-treatment in the thalamus and 
cerebellum (Th+CB) in the βgal -/- mice.  Spinal cord βgal activity was only 
slightly elevated at about 30% and 40% of control levels in the AAV-Th and AAV-
Th+CB treated βgal -/- mice, respectively.  
At 180 days of age, or 4 months post ic injection, βgal activity was 
similarly elevated in the cortex, brainstem, and cerebellum in the AAV-Th and 
AAV-Th+CB treated βgal -/- mice  (Figure 30).  Furthermore, at 4 months post ic 
injection, spinal cord βgal activity was now elevated to about 80% and 60% of 
control levels in the AAV-Th and AAV-Th+CB treated βgal -/- mice, respectively. 
βgal activity in the untreated βgal -/- mice was only about 1-2% of control βgal +/- 
levels.   
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Total Ganglioside Concentration was Reduced in the AAV-Treated Adult GM1 
Gangliosidosis Mice 
 Total CNS ganglioside concentration (µg sialic acid / 100 mg dry weight) 
was quantified in AAV-treated adult GM1 gangliosidosis mice at 1 month and 4 
months post ic injections (Figures 31 and 32, respectively).  At 90 days of age, or 
1 month post ic injection, the total ganglioside concentration in the cortex, 
brainstem, and cerebellum was significantly higher in the untreated βgal -/- mice 
than in the control mice (C) (Figure 31).  Furthermore, AAV-treatment 
significantly reduced total ganglioside concentrations in the cortex, brainstem, 
and cerebellum.  Although spinal cord ganglioside concentration was higher in 
the βgal -/- mice than in the control mice and AAV-treatment reduced ganglioside 
concentration, these differences were not statistically significant.   
At 180 days of age, or 4 months post ic injection, total ganglioside 
concentration was significantly elevated in all of the CNS regions in the untreated 
βgal -/- mice compared to the control mice (Figure 32).  AAV-Th and AAV-Th+CB 
treatment significantly reduced ganglioside concentration in all of the CNS 
regions analyzed, including the spinal cord.  
 
GM1 was Reduced in the AAV-Treated Adult GM1 Gangliosidosis Mice 
 CNS GM1 storage was quantified in AAV-treated Adult βgal -/- mice at 1 
and 4 months post ic injection by HPTLC.  The qualitative distribution of 
gangliosides in the cortex, brainstem, cerebellum, and spinal cord at 1 month 
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post ic injection are shown in Figures 33, 34, 35, and 36, respectively.   The 
quantitative distribution of individual gangliosides in the cortex, brainstem, 
cerebellum, and spinal cord at 1 month post ic injection are shown in Tables 8, 9, 
10, and 11, respectively.   Ganglioside GM1 concentration was also measured in 
βgal -/- mice at 60 days of age to determine ganglioside storage at initiation of 
treatment (Tables 8-11).  At 90 days of age or 1 month post ic injection, AAV-
treatment significantly reduced ganglioside GM1 in all of the CNS regions 
analyzed.  In fact, GM1 concentrations were lower in the AAV-treated βgal -/- 
mice at 90 days of age than in the βgal -/- mice that received no treatment at 60 
days of age.  Also, cerebellar GM1 concentrations were further reduced by the 
additional AAV-Th+CB injection.  These results suggests that AAV-treatment can 
rapidly produce lysosomal enzymes to process stored gangliosides and than 
AAV-Th+CB injections may be required to target the cerebellum.  In addition, 
gangliosides GM3 and GM2 were present in only the AAV-treated βgal -/- mice at 
1 month post ic injection (Tables 8-11). 
 The qualitative distribution of gangliosides in the cortex, brainstem, 
cerebellum, and spinal cord at 4 months post ic injection are shown in Figures 
37, 38, 39, and 40, respectively.   The quantitative distribution of individual 
gangliosides in the cortex, brainstem, cerebellum, and spinal cord at 4 months 
post ic injection are shown in Tables 12, 13, 14, and 15, respectively.   For the 
most part, ganglioside GM1 concentration was reduced at 4 months post ic 
injection in all of the CNS regions analyzed but not corrected to control βgal +/- 
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mice levels.  On the other hand, GM1 concentration in the cerebellum of the 
AAV-Th+CB treated βgal -/- mice was corrected to normal levels at 4 months 
post ic injection (Table 14).  Although not statistically significant, AAV-treatment 
in the brainstem of βgal -/- mice reduced GM1 concentration below that of the 
control βgal +/- mice (Table 13). At 180 days of age or 4 months post ic injection, 
gangliosides GM3 and GM2 were not present in the AAV-treated βgal -/- mice as 
was seen in the 1 month post ic injection time point. 
 
GA1 was Reduced in the AAV-Treated Adult GM1 Gangliosidosis Mice 
 In addition to GM1, GA1 also accumulates in the CNS of βgal -/- mice. 
The GA1 concentration in the cortex, brainstem, cerebellum, and spinal cord at 1 
month post ic injection is shown in Table 16.  GA1 was also quantified in 60-day 
old untreated βgal -/- mice to determine the amount of GA1 storage at initiation of 
treatment (Table 16).  In the cortex and brainstem, the GA1 concentrations were 
significantly reduced in the AAV-treated βgal -/- mice at 1 month post ic injection.  
Similar to the GM1 results, these reductions were also lower in the AAV-treated 
βgal -/- mice at 90 days of age than in the untreated βgal -/- mice at 60 days of 
age.  Cerebellar GA1 concentration was reduced in the AAV-Th treated βgal -/- 
mice and not detectable in the AAV-Th+CB treated βgal -/- mice.  The GA1 
concentration in the spinal cord was significantly reduced in the both the AAV-Th 
and AAV-Th+CB treated βgal -/- mice, but only mice that received the AAV-
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Th+CB treatment had GA1 reductions that were lower than the untreated βgal -/- 
mice at 60 days of age.   
 The HPTLC distribution of GA1 at 180 days of age or 4 months post ic 
injection in the cortex, brainstem, cerebellum, and spinal cord are shown in 
Figures 41, 42, 43, and 44, respectively.  The GA1 concentration in the CNS at 4 
months post ic injection is shown in Table 17. In the cortex and brainstem, the 
GA1 concentrations were not detectable in the AAV-treated βgal -/- mice at 4 
months post ic injection.  Cerebellar GA1 concentration was significantly reduced 
in the AAV-Th treated βgal -/- mice and was not detectable in the AAV-Th+CB 
treated βgal -/- mice.  The GA1 concentration in the spinal cord was significantly 
reduced in the both the AAV-Th and AAV-Th+CB treated βgal -/- mice.   
 
The Cortical Myelin-Enriched Lipid Cerebrosides is Significantly Elevated in the 
AAV-Treated Adult GM1 Gangliosidosis Mice 
 The concentration of the cortical cerebrosides at 1 and 4 months post ic 
injection in the AAV-treated βgal -/- mice are shown in Table 18.  At 90 days of 
age or 1 month post ic injection, cerebrosides, a myelin-enriched lipid is 
significantly reduced in the βgal -/- mice compared to the control βgal +/- mice. 
This is consistent with previous findings of less myelin in animal models and in 
patients with GM1 gangliosidosis (Kasama and Taketomi 1986; Kaye et al. 1992; 
Folkerth et al. 2000).  The concentration of cerebrosides in the AAV-treated βgal 
-/- mice is slightly elevated at 1 month post ic injection compared to the untreated 
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βgal -/- mice.  And at 180 days of age or 4 months post ic injection, cerebrosides 
is significantly greater in the AAV-Th treated βgal -/- mice than in the untreated 
βgal -/- mice.  Furthermore, cerebrosides increased in the AAV-treated βgal -/- 
mice from 90 to 180 days of age.  Although cerebrosides were not corrected to 
normal control levels in the AAV-treated βgal -/- mice, these results suggest that 
AAV-treatment may reverse the effects of dysmyelinogenesis in the βgal -/- mice.   
 
 Improved Motor Behavior in the AAV-Treated Adult GM1 Gangliosidosis Mice 
 Motor coordination was assessed by the rotorod and locomotor and 
rearing activity was measured using the open-field test in the βgal -/- mice at 135 
days of age or at 2.5 months post ic injection and at 180 days of age or at 4 
months post ic injection.  At 135 days of age or 2.5 months post ic injection, both 
locomotor activity and rearing in the AAV-Th treated βgal -/- mice was 
significantly improved compared to the untreated βgal -/- mice (Figure 45).  At 4 
months post ic injection, locomotor activity was similar in all of the groups (Figure 
46).  Although the number of rearing events in the AAV-treated βgal -/- mice was 
greater at 4 months post ic injection, these differences were not statistically 
significant.  The rotorod test showed no improvement in motor coordination in the 
AAV-treated βgal -/- mice at 2.5 months or at 4 months post ic injection.    
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DISCUSSION 
 
The mechanism of cross-correction allows for extensive delivery of 
lysosomal enzyme throughout the CNS.  In addition, only a relatively few cells 
would have to be modified in order to achieve widespread distribution of 
corrective enzyme (Sands and Davidson 2006).  AAV-mediated gene therapy 
has been successful in correcting neuronal pathology, improving motor deficits, 
and in some cases extending survival in several mouse models of LSDs to 
include Sandhoff disease, mucopolysaccharidosis IIIB, late infantile neuronal 
ceroid lipofuscinosis, Niemann-Pick type A, and globoid cell leukodystrophy 
(Dodge et al. 2005; Rafi et al. 2005; Cachon-Gonzalez et al. 2006; Passini et al. 
2006; Cearley and Wolfe 2007; Fu et al. 2007).  These results suggest that gene 
therapy may be a viable approach for treatment in patients.   
AAV-mediated gene delivery of βgal into the thalamus and the cerebellum 
of adult GM1 gangliosidosis mice was effective in increasing βgal enzymatic 
activity in the cortex, brainstem, cerebellum, and spinal cord.  As a result, AAV-
treatment reduced GM1 and GA1 storage and improved locomotor activity.  This 
is the first evidence that adult AAV-treatment reduces neurochemical storage and 
improves motor deficits in the GM1 gangliosidosis mice. 
βgal enzymatic activity was significantly elevated in the CNS of AAV-
treated βgal -/- mice as early as 1 month post ic injection.  This suggests that the 
AAV delivers the vector to cells and that lysosomal enzyme is trafficked and 
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distributed throughout the CNS.  Although the level of βgal expression was 
considerably greater in the AAV-treated βgal -/- mice than in the control βgal +/- 
mice, this is not likely to have a toxic effect.    Previous studies using AAV 
vectors in LSDs also showed similarly elevated expression of enzyme in the 
brain without having a significant deleterious effect (Dodge et al. 2005; Cachon-
Gonzalez et al. 2006; Cearley and Wolfe 2007).    
An interesting observation was made in the ganglioside distribution 
patterns of the AAV-treated βgal -/- mice at 1 month post ic injection.  
Gangliosides GM3 and GM2 were present in only the AAV-treated animals in all 
of the CNS regions analyzed.  This may be explained by the considerable 
amount of enzyme expression resulting from the AAV-treatment.  Due to 
significant expression of βgal, GM1 is rapidly hydrolyzed to GM2.   This may 
result in a minor buildup of gangliosides as subsequent enzymes cannot as 
rapidly catabolyze GM2 in the degradative pathway.  Furthermore, GM3 and 
GM2 were not present in the ganglioside distribution patterns at 4 months post ic 
injection, suggesting these elevations were transient perhaps from the 
considerable amount of βgal.   
Also, our results showed that at 4 months post ic injection, the GM1 
concentration in the brainstem was slightly lower in the AAV-treated βgal -/- mice 
than in the control βgal +/- mice.  However, this minor decrease was not 
important.  Previous work showed that NB-DGJ treatment in normal C57BL/6 
mice reduced GM1 content in the CNS without any adverse effects, even during 
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cerebellar development (Kasperzyk et al. 2005).   Therefore, the slight decrease 
in brainstem GM1 content in the AAV-treated GM1 gangliosidosis mice should 
not result in an adverse effect.   
In addition to restoring βgal expression and reducing GM1 and GA1, our 
results suggest that AAV-treatment may reverse the effects of 
dysmyelinogenesis in the βgal -/- mice. We show that cerebrosides, a myelin-
enriched lipid is significantly increased in the cortex of AAV-treated βgal −/− mice 
compared to the untreated βgal -/- mice at 4 months post ic injection.  
Cerebrosides were also increased between 90 to 180 days of age in the AAV-
treated βgal -/- mice. The concentration of cerebrosides is directly proportional to 
the amount of myelin and has been used as a myelin marker in remyelination 
studies in mice (Seyfried and Yu 1980; Morell and Quarles 1999; Jurevics et al. 
2002). Our results suggest that dysmyelinogenesis occurs in the βgal -/- mice 
and that remyelination can occur in the βgal -/- mice following AAV-treatment.  
Further studies will be needed to understand the role of myelin in LSDs. 
   We also show that AAV-treatment in the βgal -/- mice improves 
locomotor activity and rearing events. The cerebellum was also targeted with the 
expectation that motor coordination could be improved following AAV-treatment.  
However, rotorod performance was not improved in the AAV-treated βgal -/- 
mice. It is possible that motor coordination deficits could occur independent of 
the cerebellum.  For example, ganglioside storage in the spinal cord was not 
corrected and could account for sustained motor deficits in the GM1 
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gangliosidosis mice.  The myelin-enriched lipid, cerebrosides was not restored to 
normal levels following AAV-treatment, which could also account for poor motor 
performance.  In addition, pathogenesis in LSDs is also associated with 
microglial activation and CNS inflammation (Wada et al. 2000; Jeyakumar et al. 
2003).  It is not clear if AAV-treatment reduced inflammation and if sustained 
inflammation could result in poor rotorod performance.  
Our results suggest that AAV-mediated gene delivery to the thalamus is 
an effective approach to achieve widespread distribution of enzyme and 
correction of lysosomal storage throughout the adult mouse brain.   Gene therapy 
may be an effective approach to correcting lysosomal storage in GM1 
gangliosidosis and possibly other LSDs. 
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Figure 29. β-galactosidase activity in the CNS of βgal -/- mice that were injected 
(ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and cerebellum 
(CB) and in untreated (C) βgal +/- and βgal -/- mice at 90 days of age or 1 month 
post ic injection.  βgal activity is expressed in nmol/hour/mg protein and the 
values represent mean + SEM.  The number of independent mice analyzed was 
3 per group.  
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Figure 30. β-galactosidase activity in the CNS of βgal -/- mice that were injected 
(ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and cerebellum 
(CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of age or 4 
months post ic injection.  βgal activity is expressed in nmol/hour/mg protein and 
the values represent mean + SEM.  The number of independent mice analyzed 
was 3 per group.  
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Figure 31.  Total ganglioside concentration in the CNS of βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 90 days of age 
or 1 month post ic injection. Ganglioside concentration is expressed as µg sialic 
acid / 100 mg dry weight and the values represent mean + SEM.  The number of 
independent mice analyzed was 3 per group.   The asterisks indicate that the 
value is statistically significant from that of the untreated βgal -/- mice at P < 0.01.   
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Figure 32. Total ganglioside concentration in the CNS of βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of 
age or 4 months post ic injection. Ganglioside concentration is expressed as µg 
sialic acid / 100 mg dry weight and the values represent mean + SEM.  The 
number of independent mice analyzed was 3 per group.   The asterisks indicate 
that the value is statistically significant from that of the untreated βgal -/- mice at 
P < 0.01. 
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Figure 33. HPTLC analysis on cortical ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
90 days of age or 1 month post ic injection. The amount of ganglioside sialic acid 
spotted per lane was equivalent to approximately 1.5 µg sialic acid. The plate 
was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 34. HPTLC analysis on brainstem ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
90 days of age or 1 month post ic injection. The amount of ganglioside sialic acid 
spotted per lane was equivalent to approximately 1.5 µg sialic acid. The plate 
was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 35. HPTLC analysis on cerebellar ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
90 days of age or 1 month post ic injection. The amount of ganglioside sialic acid 
spotted per lane was equivalent to approximately 1.5 µg sialic acid. The plate 
was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 36. HPTLC analysis on spinal cord ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
90 days of age or 1 month post ic injection. The amount of ganglioside sialic acid 
spotted per lane was equivalent to approximately 1.5 µg sialic acid. The plate 
was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 37. HPTLC analysis on cortical ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
180 days of age or 4 months post ic injection. The amount of ganglioside sialic 
acid spotted per lane was equivalent to approximately 1.5 µg sialic acid. The 
plate was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 38. HPTLC analysis on brainstem ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
180 days of age or 4 months post ic injection. The amount of ganglioside sialic 
acid spotted per lane was equivalent to approximately 1.5 µg sialic acid. The 
plate was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 39. HPTLC analysis on cerebellar ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
180 days of age or 4 months post ic injection. The amount of ganglioside sialic 
acid spotted per lane was equivalent to approximately 1.5 µg sialic acid. The 
plate was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Figure 40. HPTLC analysis on spinal cord ganglioside distribution in βgal -/- mice 
that were injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the 
thalamus and cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 
180 days of age or 4 months post ic injection. The amount of ganglioside sialic 
acid spotted per lane was equivalent to approximately 1.5 µg sialic acid. The 
plate was developed by a single ascending run with chloroform: methanol: water 
(55:45:10 by volume) containing 0.02% calcium chloride.  The bands were 
visualized with the resorcinol-HCl spray. 
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Table 16:  GA1 Concentration  in Adult !gal Mice, 1 month post AAV transplantationa
Strain Treatment Ageb
   
!gal -/- - 60 2.24 + 0.11 1.72 + 0.02  1.35 + 0.07 1.00 + 0.03
!gal +/- - 90
!gal -/- - 90 2.58 + 0.08 2.33 + 0.22 2.52 + 0.08 1.70 + 0.12
!gal -/- PBS 90 2.56 + 0.10 2.49 + 0.16 2.28 + 0.15 1.77 + 0.04
!gal -/- AAV-Th 90 0.31 + 0.01 * 0.37 + 0.15 * 1.27 + 0.10 * 1.20 + 0.09 *
!gal -/- AAV-Th+CB 90 0.31 + 0.01 * 0.17 + 0.06 * * 0.75 + 0.15 *
a   Concentration expressed as mg / 100 mg dry weight.  Values represent mean + SEM, where 3 independent samples were analyzed per group.
b   Age of mice at time of analysis in days
N.D., not detectable
The asterisks indicate that the value is significantly different from that of the untreated !gal -/- mice at *P< 0.01.
 
N.D.
N.D. N.D. N.D. N.D.
Cerebellum
 
Spinal Cord
 
Cortex Brainstem
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Figure 41. HPTLC of cortical GA1 distribution in βgal -/- mice that were injected 
(ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and cerebellum 
(CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of age or 4 
months post ic injection. The amount of sample spotted per lane was equivalent 
to approximately 0.2 mg tissue dry weight. The plate was developed by a single 
ascending run with chloroform: methanol: water (65:35:8 by volume) containing 
0.02% calcium chloride.  The bands were visualized with the orcinol-H2SO4 
spray.  
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Figure 42. HPTLC of brainstem GA1 distribution in βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of 
age or 4 months post ic injection. The amount of sample spotted per lane was 
equivalent to approximately 0.2 mg tissue dry weight. The plate was developed 
by a single ascending run with chloroform: methanol: water (65:35:8 by volume) 
containing 0.02% calcium chloride.  The bands were visualized with the orcinol-
H2SO4 spray.  
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Figure 43. HPTLC of cerebellar GA1 distribution in βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of 
age or 4 months post ic injection. The amount of sample spotted per lane was 
equivalent to approximately 0.2 mg tissue dry weight. The plate was developed 
by a single ascending run with chloroform: methanol: water (65:35:8 by volume) 
containing 0.02% calcium chloride.  The bands were visualized with the orcinol-
H2SO4 spray.  
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Figure 44. HPTLC of spinal cord GA1 distribution in βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of 
age or 4 months post ic injection. The amount of sample spotted per lane was 
equivalent to approximately 0.2 mg tissue dry weight. The plate was developed 
by a single ascending run with chloroform: methanol: water (65:35:8 by volume) 
containing 0.02% calcium chloride.  The bands were visualized with the orcinol-
H2SO4 spray.  
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Table 17:  GA1 Concentration  in Adult !gal Mice, 4 months post AAV transplantationa
Strain Treatment Ageb
   
!gal +/- - 180
!gal -/- - 180 5.12 + 0.14 3.84 + 0.07 3.04 + 0.04 2.64 + 0.12
!gal -/- PBS 180 5.15 + 0.30 3.87 + 0.06 3.07 + 0.11 2.77 + 0.14
!gal -/- AAV-Th 180 0.81 + 0.41 * 0.93 + 0.51 *
!gal -/- AAV-Th+CB 180 * 0.52 + 0.15 *
a   Concentration expressed as mg / 100 mg dry weight.  Values represent mean + SEM, where 3 independent samples were analyzed per group.
b   Age of mice at time of analysis in days
N.D., not detectable
The asterisks indicate that the value is significantly different from that of the untreated !gal -/- mice at *P< 0.01.
Cortex Brainstem
  
N.D.
Cerebellum
 
Spinal Cord
 
N.D.
N.D. N.D. N.D.
N.D.
N.D.
N.D.
N.D.
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Table 18: Cortical Cerebrosides Concentration  in Adult !gal Micea
Strain Treatment  
   
!gal +/- - 2.43 + 0.14 2.64 + 0.23  
!gal -/- - 1.45 + 0.15 # 1.44 + 0.05 #
!gal -/- PBS 1.40 + 0.25 # 1.30 + 0.09 #
!gal -/- AAV-Th 1.70 + 0.16 2.14 + 0.34 *
!gal -/- AAV-Th+CB 1.73 + 0.16 1.86 + 0.23
a   Concentration expressed as mg / 100 mg dry weight.  
Values represent mean + SEM, where 3 independent samples were analyzed per group.
* Indicates that the value is significantly different from that of the untreated !gal -/- mice at P < 0.01.
# Indicates that the value is significantly different from that of the untreated !gal +/- mice at P < 0.05.
1 month post ic
(90 days of age)
4 months post ic
(180 days of age)
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Figure 45. Locomotor activity and Rearing events in βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 135 days of 
age or 2.5 months post ic injection. Values represent mean + SEM.  The number 
of independent mice analyzed was 14-18 per group.  The asterisks indicate that 
the values is statistically significant from that of the untreated βgal -/- mice at P < 
0.01.   
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Figure 46. Locomotor activity and Rearing events in βgal -/- mice that were 
injected (ic) with AAV-βgal (T) into the thalamus (Th) or into the thalamus and 
cerebellum (CB) and in untreated (C) βgal +/- and βgal -/- mice at 180 days of 
age or 4 months post ic injection. Values represent mean + SEM.  The number of 
independent mice analyzed was 14-18 per group.  
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Figure 47. Rotorod performance at 20 rpm in βgal -/- mice that were injected (ic) 
with AAV-βgal (T) into the thalamus (Th) or into the thalamus and cerebellum 
(CB) and in untreated (C) βgal +/- and βgal -/- mice at 135 days of age or 2.5 
months post ic injection and at 180 days of age or 4 months post ic injection. 
Values represent mean + SEM.  The number of independent mice analyzed was 
14-18 per group.  
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CHAPTER SIX 
Comparative Analysis of Brain Lipids in Mice, Cats, and Humans with Sandhoff 
Disease 
 
INTRODUCTION 
 
The development of mouse models of lysosomal storage disorders has 
provided tools for advancement in possible therapies and treatments.   Despite 
some success in bone marrow transplantation, gene therapy, stem cell therapy, 
and substrate reduction therapy in SD mice  (Norflus et al. 1998; Andersson et al. 
2004; Cachon-Gonzalez et al. 2006; Lee et al. 2007), there are still no treatments 
available for patients.   
A possible disconnect from mouse studies to clinical treatments is the 
difference in brain size between mice and humans.   The brain weight of a mouse 
is around 0.4 grams while an infantile human brain weighs around 400 grams, 
representing a 1000-fold difference in size (Hofman 1984; Haug 1987; Roth and 
Dicke 2005).  The fGM2Baker cats were previously characterized as authentic SD 
cats with similar behavioral and disease progression as the SD human (Cork et 
al. 1977; Baker et al. 1979; Martin et al. 2004).   Although the feline brain is 
closer in size to a human brain, it is not clear how the mouse and cat animal 
models of SD compare to the SD patient. 
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  In this study, I compared the brain lipids in mice, cats, and humans with 
SD.  This is the first comparative analysis of brain lipids in the SD mouse, cat, 
and human. This study could help bridge the gap between the successes in 
mouse studies to treatment in patients.  
 
MATERIALS AND METHODS 
 
Mice 
 SD (Hexb -/-) mice were used for this study and are described in Chapter 
2.  The cortex of 4-month-old SD mice were collected and stored at -80°C. All 
animal experiments were carried out with ethical committee approval in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care 
Committee. 
  
Cats 
 The pathology in the fGM2Baker cat was previously described (Cork et al. 
1977; Baker et al. 1979).  The causative mutation in the fGM2Baker cats results 
from a 25-base-pair inversion at the 3’ end of the Hexb gene (Martin et al. 2004).   
Therefore, the fGM2Baker cat represents an authentic model to study Sandhoff 
disease.   
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Human Samples 
Age-matched normal and SD human cortex samples were obtained from 
the NICH Brain and Tissue Bank for Developmental Disorders at the University of 
Maryland, Baltimore, MD.   
 
Isolation and Purification of Lipids 
  Lipids were isolated and purified using the described methods in Chapter 2. 
 
Analysis of Lipids by HPTLC 
 Lipids were analyzed by HPTLC as previously described in Chapter 2. 
 
Statistical Analysis 
 Data were analyzed by the unpaired Student’s t-Test to calculate 
statistical significance between the normal and the SD samples using Statview 
5.0 software.   
 
RESULTS 
 
Cortical GM2 and GA2 Accumulation Mice, Cats, and Human with Sandhoff 
Disease 
 The objective of this study was to compare the total brain lipid distribution 
between mice, cats, and human with Sandhoff disease (SD). Although we report a 
single SD human sample in our analyses, historical SD human data confirms our 
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findings (Sandhoff et al. 1989).  The total brain ganglioside concentration was 
significantly elevated in the SD mouse, cat, and human compared to the normal 
strain of each species (Table 19). The quantitative and qualitative distribution of 
individual gangliosides in the mice, cats, and human with SD is shown in Table 20 
and in Figure 48.  The most significant finding was that GM2 comprised 38%, 67%, 
and 85% of the total brain ganglioside distribution in the SD mice, cats, and 
human, respectively.  The concentrations of the other gangliosides (GM1, GD1a, 
GT1a/LD1, GD1b, GT1b, and GQ1b) were generally similar between the normal 
and the SD animal for both mice and cats, suggesting that the increase in total 
ganglioside concentration stems from mostly GM2 accumulation.    The 
concentration of the other gangliosides (GM1, GD1a, GD1b, GT1b, and GQ1b) in 
the SD human was less than in the normal human, which is consistent with 
historical data (Sandhoff et al. 1989).   
   GA2 also accumulates in SD mice, cats, and human (Figure 49 and Table 
21).  GA2 is derived from GM2 through the action of a sialidase.  Therefore, we 
looked at the relative ratio of GA2 to GM2 storage (Figure 50).  Interestingly, the 
GA2/GM2 ratio was significantly greater in the SD mouse than in the SD cat or SD 
human.  These findings suggest that the GSL storage seen the SD cat is 
intermediate between that of the SD mouse and SD human.  
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Qualitative and Quantitative Distribution of Neutral and Acidic Lipids in Mice, 
Cats, and Human with Sandhoff Disease 
 The qualitative distribution of the neutral and acidic brain lipids in mice, cats, 
and human with Sandhoff disease (SD) is shown in Figures 51 and 52, 
respectively.  The myelin-enriched glycolipids, cerebrosides and sulfatides were 
significantly lower in the SD mice compared to the normal mice and undetectable 
in the SD human compared to the normal human (Figures 51 and 52 and Table 
21).  These findings are consistent with previous reports of lower cerebrosides and 
sulfatides in the SD mice and the SD humans (Sandhoff et al. 1989; Denny et al. 
2006).   In addition, the myelin-enriched lipids were significantly reduced in the SD 
cat by about 88% compared to the normal cat.  The myelin lipid reductions in the 
SD cat were intermediate to that in the SD mouse and SD human.  No major 
differences were observed between the control and the SD animal for each 
species analyzed for the distribution or content of the major neutral lipids 
(cholesterol, ceramide, phosphatidylethanolamine, phosphatidylcholine, 
sphingomyelin) or acidic phospholipids (cardiolipin, phosphatidylserine, 
phosphatidylinositol) (Figures 51 and 52). 
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DISCUSSION 
 
Our results show for the first time the comparative analysis of brain lipids 
in mice, cats, and human with SD.  We show that GM2 accumulation in the SD 
cat was intermediate of the SD mouse and the SD human.  In addition to GM2, 
GA2 also accumulates in SD (Sandhoff et al. 1971; Gravel et al. 1995; Sango et 
al. 1995; Denny et al. 2006).  The relative GA2/GM2 ratio in the SD mouse was 
significantly greater than in the SD cat or SD human.  It has been previously 
shown that sialidase in SD mice is more enhanced than in SD humans and is 
able to convert significant amounts of GM2 to GA2 (Sango et al. 1995; Yuziuk et 
al. 1998; Bertoni et al. 1999).  Our findings support these results and suggest 
that the SD cat falls between the SD mouse and the SD human with respect to 
GSL accumulation.  
Pathogenesis in lysosomal storage diseases is also associated with 
hypomyelination (Sandhoff et al. 1971; Kaye et al. 1992; Kroll et al. 1995; 
Folkerth et al. 2000).  Reductions in the myelin-enriched lipids, cerebrosides and 
sulfatides were previously shown in SD mice and in patients with GM2 
gangliosidoses (Sandhoff et al. 1971; Pellkofer and Jatzkewitz 1974; Denny et al. 
2006).  MRI analysis also revealed significant white matter changes in the brains 
of patients and in different animal models of GSL storage disorders (Kaye et al. 
1992; Kroll et al. 1995; Folkerth et al. 2000; van der Voorn et al. 2005; Vite et al. 
2007).  In addition, low angle X-ray diffraction analysis in the optic nerves of SD 
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mice also showed that the CNS was hypomyelinated (McNally et al. 2007).  Our 
results support these studies and we also show that the myelin-enriched lipids, 
cerebrosides and sulfatides are also significantly reduced in the SD cat 
compared to the normal cat.  Like GM2 accumulation, the myelin-enriched lipid 
reduction in the SD cat is intermediate of the SD mouse and the SD human.  
Our results suggest that the lipid abnormalities in the SD cat are generally 
intermediate between the SD mouse and the SD patient.   Therapeutic 
experiments in the SD cat should be a critical step in developing clinical 
treatments for SD patients. 
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Table 19: Total Brain Ganglioside Concentration in Mice, Cats, and Human with Sandhoff diseasea
Species  Nb
  
Mouse Normal 3 531 + 9
Sandhoff 3 858 + 30
     
Cat Normal 3 499 + 14
Sandhoff 4 1305 + 122
Human Normal 1
Sandhoff 1
a   Values represent mean + SEM.  
b   N, the number of independent samples analyzed.
c
 Concentration expressed as µg sialic acid / 100 mg dry weight.
434
Total Ganglioside Concentrationc
1613
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Figure 48. HPTLC analysis of cortical gangliosides in mouse (M), cat (C), and 
human (H) with Sandhoff disease.  The amount of ganglioside sialic acid spotted 
per lane was equivalent to 1.5 µg sialic acid.  The plate was developed in one 
ascending run with chloroform: methanol: 0.02% aqueous calcium chloride 
(55:45:10 by vol).  Gangliosides were visualized with resorcinol-HCl spray.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 188 
 
 
 
 
 
 
 
 189 
Figure 49. HPTLC analysis of cortical GA2 in mouse (M), cat (C), and human (H) 
with Sandhoff disease.  The amount of sample spotted per lane was equivalent 
to 100 µg brain dry weight.  The plate was developed in one ascending run with 
chloroform: methanol: 0.02% aqueous calcium chloride (65:35:8 by vol).  
Asialogangliosides were visualized with orcinol-H2SO4 spray.  
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Table 21:  Neutral and Acidic Brain Glycosphingolipids in Mice, Cats, and Human with Sandhoff diseasea
Species  Nb
  
Mouse Normal 3 2.64 + 0.24 0.52 + 0.01
Sandhoff 3 4.65 + 0.07 1.53 + 0.21 * 0.39 + 0.02 **
           
Cat Normal 3 4.17 + 0.84 0.76 + 0.15
Sandhoff 4 1.72 + 0.11 0.46 + 0.32 ** 0.10 + 0.06 **
Human Normal 1
Sandhoff 1
a   Values represent mean + SEM.
b   N, the number of independent samples analyzed.
c
 Determined from densitometric scanning of HPTLC as shown in Fig 49.
d
 Determined from densitometric scanning of HPTLC as shown in Fig 51.
e
 Determined from densitometric scanning of HPTLC as shown in Fig 52.
f   N.D., not detectable
The asterisks indicate that the value is significantly different from the normal strain at  *P< 0.05 and at **P< 0.01 as determied by the two-tailed test.
GA2 Concentrationc
(mg / 100 mg dry weight)
N.D.
5.29
N.D.f
N.D.
N.D.
Sulfatidese
(mg / 100 mg dry weight)
Cerebrosidesd
(mg / 100 mg dry weight)
N.D.
0.662.20
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Figure 50.  Relative GA2 to GM2 ratio in Sandhoff disease mice (N = 3), cats (N 
= 4), and human (N = 1).  Values represent mean + SEM.  The asterisks indicate 
that the values are significantly different at P < 0.01.   
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Figure 51.  HPTLC of cortical neutral lipids in mouse (M), cat (C), and human (H) 
with Sandhoff disease.   The amount of neutral lipids spotted per lane was 
equivalent to approximately 70 µg brain dry weight.  The plate was developed to 
a height of 4.5 cm with chloroform: methanol: acetic acid: formic acid: water 
(35:15:6:2:1 by volume), then developed to the top with hexanes: diisopropyl 
ether: acetic acid (65:35:2 by volume).  The bands were visualized by charring 
with 3% cupric acetate in 8% phosphoric acid solution.  CE, cholesterol esters; 
TG, triglycerides; IS, internal standard; Chol, cholesterol; CM, ceramide; CB, 
cerebroside (doublet); PE, phosphatidylethanolamine; PC, phosphatidlycholine; 
SM, sphingomyelin. 
 
 
 
 
 
 
 
 
 
 
 
 
 195 
 
 
 
 
 
 
 
 196 
Figure 52. HPTLC of cortical acidic lipids in mouse (M), cat (C), and human (H) 
with Sandhoff disease.   The amount of acidic lipids spotted per lane was 
equivalent to approximately 200 µg brain dry weight.  The plate was developed to 
a height of 6 cm with chloroform: methanol: acetic acid: formic acid: water 
(35:15:6:2:1 by volume), then developed to the top with hexanes: diisopropyl 
ether: acetic acid (65:35:2 by volume).  The bands were visualized by charring 
with 3% cupric acetate in 8% phosphoric acid solution.  FA, fatty acids; IS, 
internal standard; CL, cardiolipin; PA, phosphatidic acid; Sulf, sulfatides 
(doublet); PS, phosphatidylserine; PI, phosphatidyinositol. 
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CHAPTER SEVEN 
CONCLUSION 
 
  The ganglioside storage diseases GM1 gangliosidosis and Sandhoff 
disease, are rare diseases that belong to a group of disorders called lysosomal 
storage diseases (LSDs).  As a group, LSDs comprise of 41 distinct diseases 
with a combined occurrence of 1 in 7700 live births (Meikle et al. 1999).  
Therefore, the LSDs represent a significant health problem.  Although the 
etiology of GM1 gangliosidosis and Sandhoff disease has been known for many 
years, there are no treatments available for patients (Gravel et al. 1995; Suzuki 
et al. 1995).   
 My dissertation research tested different therapeutic approaches for the 
early intervention treatment of the ganglioside storage diseases, GM1 
gangliosidosis and Sandhoff disease. Ganglioside accumulation commences 
early during neonatal periods in the mouse models of GM1 gangliosidoses and 
Sandhoff disease, therefore, the goal was to initiate substrate reduction therapy, 
stem cell therapy, and AAV gene therapy during neonatal ages and analyze the 
neurochemical result (Kasperzyk et al. 2004; Baek et al. 2007).   
AAV gene therapy had the greatest efficacy in normalizing the GSL 
storage as an early intervention therapy.  As a result, I also tested AAV mediated 
gene therapy in the adult GM1 gangliosidosis mice, when there is significant GSL 
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storage.  I also suggested that the SD cat could be an important intermediate 
model to test different therapies before human application.  
Substrate reduction therapy (SRT) in neonatal Sandhoff disease mice was 
effective in reducing GM2 accumulation in the brain.  This study also showed that 
ganglioside accumulation commenced as early as postnatal day 2 (p-2) in the SD 
mice.  But most significantly, SRT using NB-DGJ in neonatal SD mice was 
effective in reducing GM2 without producing any adverse side effects (body 
weight reduction, brain weight reduction, etc.).   SRT has previously focused on 
using the glucose analog of NB-DGJ, NB-DNJ (miglustat, Zavesca®).  However, 
many reports have shown that Zavesca® produces adverse effects such as 
significant weight loss, diarrhea, and GI tract distress in both patients and in 
mice, which may not be suitable for an early intervention therapy (Andersson et 
al. 2004; Bembi et al. 2006; Priestman et al. 2008).  My study emphasized the 
effectiveness of NB-DGJ for SRT without producing adverse effects especially 
during early development.  These results suggest that SRT using NB-DGJ is an 
effective early intervention therapy for Sandhoff disease and possibly other GSL 
storage disorders (Baek et al. 2007).   
My study using neural stem cells (NSCs) was the first to prove that a cell-
based therapy could restore cellular function and prolong life in the Sandhoff 
disease mice.  My collaborators on this study, Drs. Jean-Pyo Lee and Evan 
Snyder at the Burnham Institute for Medical Research showed that neonatal 
transplantation of NSCs migrated throughout the cortex and I showed that NSCs 
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reduced neurochemical storage. (Lee et al. 2007).  Although we showed that 
NSCs improved survival in the Sandhoff disease mice, it is not clear if NSC 
therapy improved motor coordination or behavior.  It would also be interesting to 
determine if NSC therapy initiated at later ages would also produce similar 
results.   
AAV-mediated gene therapy in neonatal GM1 gangliosidosis mice was 
effective at restoring enzymatic activity and correcting neurochemical storage.  In 
addition, AAV therapy also corrected secondary GSL alterations (cerebrosides 
and sulfatides).  Due to these successful results, we administered AAV gene 
therapy in adult GM1 gangliosidosis mice.  Adult AAV treatment elevated 
enzymatic activity and significantly reduced GSL storage throughout the CNS of 
GM1 gangliosidosis mice.  Furthermore, AAV-mediated gene therapy was 
successful at improving locomotor activity in adult GM1 gangliosidosis mice.  
These studies are the first to show that AAV-mediated gene therapy in GM1 
gangliosidosis mice completely corrected GSL storage in the neonatal mice and 
improved behavior in the adult mice (Broekman et al. 2007), and should be 
considered for human application. 
 These results have contributed to the formation of the Tay-Sachs Gene 
Therapy Consortium between 4 global institutions including Boston College, 
Massachusetts General Hospital, Auburn University, and Cambridge University.  
The goal of the consortium is to bring AAV-mediated gene therapy to clinical 
trials to patients within 3-4 years.  Currently, the consortium is researching how 
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to scale up experiments from mouse studies to patient use and to determine AAV 
vector dosages.  In my dissertation, I suggested using the SD cat as an 
intermediate model to test and develop potential therapies for patients and 
analyzed the glycolipid storage in mice, cats, and human with SD. I showed that 
the GSL accumulation in the SD cat was generally intermediate between the SD 
mouse and the SD human.  Therefore, the SD cat could be an important 
intermediate model to help bridge the success seen in mice to treatment in 
humans. 
Hypomyelination occurs in several LSDs as myelin reductions have been 
documented in patients and in animal models of LSDs (Sandhoff et al. 1989; 
Kaye et al. 1992; Denny et al. 2006; McNally et al. 2007).  I showed that AAV-
mediated gene therapy corrected the myelin-enriched lipids, cerebrosides and 
sulfatides in neonatal GM1 gangliosidosis mice.   Additionally, cerebrosides were 
significantly elevated in the AAV-treated adult GM1 gangliosidosis mice, 
suggesting that the effects of hypomyelination could be reversed.  Furthermore, 
we show for the first time that cerebrosides is significantly reduced in the SD cat 
compared to the normal cat, consistent with MRI findings (Kroll et al. 1995).  
Throughout my dissertation, myelin was quantified by measuring the 
concentrations of cerebrosides and sulfatides by HPTLC.  Further studies such 
as myelin immunohistochemistry and low-angle X-ray diffraction will be needed 
to confirm these findings and to evaluate the role of myelin in LSD pathogenesis.   
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Disease progression in GSL storage diseases is also associated with 
neuroinflammation, which has been a hallmark of pathogenesis in the mouse 
models of GM1 gangliosidosis and Sandhoff disease (Wada et al. 2000; 
Myerowitz et al. 2002; Jeyakumar et al. 2003; Jeyakumar et al. 2004; Wu and 
Proia 2004). The inflammatory cascade consists of microglial activation, pro-
inflammatory cytokine production, and infiltration of macrophages in the brain, 
which precedes neurodegeneration (Wada et al. 2000; Myerowitz et al. 2002; 
Jeyakumar et al. 2003; Wu and Proia 2004).  It was previously shown that non-
steroidal anti-inflammatory drugs improved motor behavior and extended survival 
in the SD mice (Jeyakumar et al. 2004). In addition, caloric restriction, which has 
long been recognized as a natural anti-inflammatory therapy, also improved 
motor performance and longevity in the SD mice (Denny et al. 2006; Holloszy 
and Fontana 2007).  Further work will also be needed to evaluate the role of CNS 
inflammation in LSDs.    
It is likely that a combination of therapies to target GSL accumulation, 
hypomyelination, and inflammation may be needed for efficacy in patients. It has 
been shown in SD mice, that combining bone marrow transplantation with SRT, 
NSCs with SRT, and non-steroidal anti-inflammatory drugs with SRT 
synergistically increased survival compared to the individual treatments 
(Jeyakumar et al. 2001; Jeyakumar et al. 2004; Lee et al. 2007).  Furthermore, 
individual treatments may need to be applied at different time points leading to a 
combinatory approach.  For example, SRT using NB-DGJ could be initiated in 
 203 
utero, when GSL biosynthesis is rapid to slow down ganglioside accumulation.  
After birth, AAV-mediated gene therapy could be then be applied.  A combinatory 
approach to disease management may be necessary for targeting the multiple 
aspects of LSDs.   
Taken together, I investigated different therapeutic approaches for GM1 
gangliosidosis and Sandhoff disease and my findings suggest that early 
intervention therapy should provide the best chance for success in patients.  
Moreover, AAV-mediated gene therapy provided the greatest level of correction 
at neonatal ages and functional improvement in adult GM1 gangliosidosis mice. 
Furthermore, therapies should be evaluated in a larger animal model of LSDs to 
devise therapeutic approaches that can be translated into treatment for patients.   
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